SZT2-Related Developmental and Epileptic Encephalopathy

Mendelian MONDO:0014201 Pathograph 16 Show in embeddings browser Neurodevelopmental Disorder Genetic Disease

SZT2-related developmental and epileptic encephalopathy (DEE18) is a rare autosomal recessive neurodevelopmental disorder caused by biallelic loss-of-function variants in SZT2, which encodes the largest subunit of the KICSTOR complex (KPTN, ITFG2, C12orf66, SZT2). KICSTOR tethers GATOR1 to the lysosomal surface, and it is that tether which allows amino-acid deprivation to switch mTORC1 off. Losing SZT2 therefore leaves mTORC1 constitutively lysosome-bound and active regardless of nutrient status, placing DEE18 among the genetic mTORopathies alongside TSC1/TSC2, DEPDC5, and NPRL2/NPRL3. The core clinical picture is early-onset, frequently drug-resistant epilepsy with global developmental delay and macrocephaly, characteristically accompanied by a thick and short corpus callosum with a persistent cavum septum pellucidum; cortical dysplasia, periventricular nodular heterotopia, and in some individuals a progressive loss of central myelination are also reported. Severity tracks residual SZT2 function: biallelic null genotypes give the severe early-onset encephalopathy, whereas biallelic missense genotypes can produce mild partial epilepsy with favourable outcome or, in a few individuals, no seizures at all.

Ask OpenScientist

Ask a research question about SZT2-Related Developmental and Epileptic Encephalopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal recessive HP:0000007

DEE18 requires two pathogenic SZT2 alleles. Both homozygous genotypes, more common in consanguineous families, and compound heterozygous genotypes are reported.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:23932106 SUPPORT Human Clinical

"mutations in SZT2 cause a severe type of autosomal-recessive infantile encephalopathy with intractable seizures and distinct neuroradiological anomalies"

The founding report states the recessive mode of inheritance.

Discussions and Knowledge Gaps

Would mTOR inhibition with sirolimus or everolimus, effective in other genetic mTORopathies, reduce seizure burden in SZT2-related DEE, and would any benefit require treatment before the progenitor-expansion window has closed?

KNOWLEDGE GAP OPEN gap_mtor_inhibitor_repurposing_in_szt2

Attached to

pathophysiology#Constitutive mTORC1 Hyperactivation pathophysiology#Excess Outer Radial Glial Cell Production

The mechanism converges on constitutive mTORC1 hyperactivation, the same node that mTOR inhibitors target in tuberous sclerosis complex, so repurposing is biologically motivated. No published clinical trial or treated case series exists for SZT2. The timing question is the substantive one: the organoid data place a large part of the pathology in progenitor amplification during early cortical development, which is complete long before a genetic diagnosis is typically made. If the macrocephaly and cortical malformation are developmentally fixed, an mTOR inhibitor started postnatally could at best address the residual excitability arm, and a trial designed around structural or head-circumference endpoints would be measuring the wrong thing.

Proposed experiments

Rapamycin rescue as a function of treatment onset in SZT2-mutant organoids

exp_rapamycin_timing_window_organoid

Treat SZT2-mutant cerebral organoids with rapamycin starting at successively later stages of organoid development and score outer radial glial cell number, upper-layer neuron number, and mTORC1 activity, to establish whether the progenitor phenotype remains correctable once cortical expansion is underway.

Show evidence (2 references)

PMID:41535455 SUPPORT In Vitro

"Our data suggest that SZT2 dysfunction may cause macrocephaly through dysregulation of mTORC1 in early neural development."

Places the progenitor mechanism in early development, which is what creates the therapeutic-window problem.

PMID:28199306 SUPPORT In Vitro

"several KICSTOR components are mutated in neurological diseases associated with mutations that lead to hyperactive mTORC1 signalling"

Places SZT2 in the mTORopathy family whose therapy is being considered for reuse.

Does SZT2 loss lower neuronal excitability threshold directly, or is the epilepsy entirely secondary to the cortical malformation produced by mTORC1-driven progenitor expansion?

KNOWLEDGE GAP OPEN gap_seizure_threshold_arm_independent_of_malformation

Attached to

pathophysiology#Lowered Intrinsic Seizure Threshold pathophysiology#Brain Overgrowth and Cortical Malformation

Two arms converge on hyperexcitability in this model. The malformation arm is well evidenced in human imaging and organoids. The intrinsic-threshold arm rests on mouse genetics - Szt2 was named for its effect on seizure threshold - and no study has isolated it from structural change in a mammalian brain. The distinction is testable and consequential: individuals with biallelic missense genotypes can have epilepsy without the severe malformations, which is difficult to explain if malformation were the whole story, but that observation is confounded because milder genotypes also produce milder structural change. If the intrinsic arm is real, seizure control would not require reversing a structural abnormality.

Proposed experiments

Excitability after adult-onset conditional Szt2 deletion

exp_adult_onset_szt2_deletion_excitability

Delete Szt2 conditionally in adult mouse forebrain neurons, after cortical development is complete, and measure seizure threshold to pentylenetetrazol and kindling rate alongside histology, to test whether excitability changes arise in the absence of any developmental malformation.

Show evidence (2 references)

PMID:23932106 SUPPORT Model Organism

"Although the molecular role of the peroxisomal protein SZT2 in neuronal excitability and brain development remains to be defined, Szt2 has been shown to influence seizure threshold and epileptogenesis in mice"

States both the seizure-threshold finding and that its molecular basis is undefined.

PMID:37213690 SUPPORT Human Clinical

"This study suggested that SZT2 variants were potentially associated with partial epilepsy with favorable outcomes without NDD, expanding the phenotypic spectrum of SZT2."

Documents epilepsy occurring without neurodevelopmental abnormality, which is the human observation that motivates a malformation-independent arm.

Does the SZT2 brain-organoid model, which carries in-frame 28-residue deletions rather than the truncating variants that predominate in patients, report the same lesion as human biallelic-null disease, and are outer radial glia the right cell type to carry the mechanism given their scarcity in the mouse models that established the seizure-threshold arm?

HUMAN MODEL MISMATCH OPEN mismatch_organoid_hypomorph_versus_patient_null

Attached to

pathophysiology#Excess Outer Radial Glial Cell Production pathophysiology#Excess Upper-Layer Cortical Neuron Generation

The organoid study is the only model of the human cortical mechanism, and it is a genuine advance precisely because outer radial glia are far more abundant in human than in mouse cortex - so the mouse literature that established the seizure-threshold arm structurally cannot address this branch. But the CRISPR alleles used are in-frame deletions of 28 residues at the distal end of exon 3, described by the authors as of uncertain functional impact, whereas most patient alleles are predicted null. A hypomorph in a human model and a null in a mouse model between them leave the human null cortical phenotype uninterrogated, so the magnitude of progenitor expansion in patient brain remains an extrapolation.

Proposed experiments

Isogenic null versus in-frame-deletion SZT2 organoid comparison

exp_isogenic_null_versus_inframe_organoids

Generate isogenic organoid lines carrying a truncating SZT2 null allele alongside the published in-frame deletion, and compare mTORC1 activity, outer radial glial number, and upper-layer neuron number, to establish whether the published phenotype under-reports the human null lesion.

Show evidence (3 references)

PMID:41535455 SUPPORT In Vitro

"the introduced mutations result in in-frame deletions of 84 bp (28 amino acid residues), corresponding to the distal portion of exon 3"

Documents that the model allele is an in-frame deletion, not a truncating null.

PMID:41535455 SUPPORT In Vitro

"oRGCs are more abundant in humans than in mice, and contribute to the expansion of the human brain by differentiating into upper-layer neurons"

States the species difference that makes mouse models unable to test this arm.

PMID:23932106 SUPPORT Human Clinical

"all three mutations are predicted to result in nonsense-mediated mRNA decay and/or premature protein truncation"

Establishes that patient alleles are typically null, unlike the model allele.

Is the progressive loss of central myelination reported in some individuals with SZT2-related DEE a consequence of mTORC1 dysregulation in oligodendroglia, a consequence of sustained seizure burden, or an unrelated feature of the severe end of the spectrum?

KNOWLEDGE GAP OPEN gap_leukoencephalopathy_relationship_to_mtorc1

Attached to

pathophysiology#Progressive Loss of Central Myelination

Progressive myelin loss is documented on serial imaging but is not universal, and the mechanistic account curated here stops at the observation. mTORC1 has well-established roles in oligodendrocyte differentiation and myelination, so a direct route is plausible, but so is a seizure-burden explanation, and the single detailed case had a complex terminal course. Nothing in the published literature separates these. The distinction matters for prognosis: a directly mTORC1-dependent myelin phenotype would be a candidate target for mTOR inhibition, whereas a seizure-driven one would not.

Proposed experiments

Oligodendrocyte-lineage-restricted Szt2 deletion and myelination

exp_oligodendrocyte_specific_szt2_deletion

Delete Szt2 selectively in the oligodendrocyte lineage in mice, in the absence of neuronal deletion and therefore of seizures, and quantify myelin thickness, oligodendrocyte maturation markers, and mTORC1 activity over time to test whether myelin loss is cell-autonomous to the oligodendrocyte lineage.

Show evidence (2 references)

PMID:29696782 SUPPORT Human Clinical

"This case expands our clinical understanding of the SZT2-phenotype and emphasizes the role of this gene in the diagnostic investigation for EOEE and leukoencephalopathies."

Establishes the white-matter phenotype while leaving its mechanism open.

PMID:29696782 SUPPORT Human Clinical

"Reported imaging findings include atrophy and dysgenesis of the corpus callosum"

Prior imaging reports describe callosal change but not progressive myelin loss, underlining that this feature is neither universal nor mechanistically explained.

⚙

Pathophysiology

Biallelic SZT2 Loss-of-Function Variant

Two pathogenic SZT2 alleles are present. Most reported alleles are truncating - nonsense, frameshift, or canonical splice-site - and are predicted to trigger nonsense-mediated decay or premature protein truncation; missense alleles that retain partial function are also reported. This node records the genomic lesion only.

neuron CL:0000540

Downstream

Loss of Functional SZT2 Protein Truncation or transcript decay removes the SZT2 scaffold protein.

Show evidence (2 references)

PMID:23932106 SUPPORT Human Clinical

"Using whole-exome sequencing, we identified biallelic mutations in seizure threshold 2 (SZT2) in both affected children."

Establishes biallelic SZT2 variants as the causal lesion.

PMID:23932106 SUPPORT Human Clinical

"all three mutations are predicted to result in nonsense-mediated mRNA decay and/or premature protein truncation and thereby loss of SZT2 function"

Characterizes the variant class as loss of function.

Loss of Functional SZT2 Protein

The ~380 kDa SZT2 scaffold protein is absent or reduced. SZT2 has no enzymatic activity and no strong homology to other proteins; its role is purely structural, which is why loss of the protein and loss of the complex are distinct steps.

Downstream

Disassembly of the KICSTOR Complex SZT2 is the subunit that links the other three components together, so its loss dissolves the complex.

Show evidence (1 reference)

PMID:28199306 SUPPORT In Vitro

"four proteins of unknown function encoded by the KPTN, ITFG2, C12orf66, and SZT2 genes and of predicted molecular weights of 48, 49, 50, and 380 kDa, respectively"

Identifies SZT2 as the 380 kDa component of the complex.

Disassembly of the KICSTOR Complex

Without SZT2 the KPTN-ITFG2 heterodimer and C12orf66 no longer assemble into the high-molecular-weight KICSTOR complex. This is a complex-integrity failure, upstream of and separable from where GATOR1 ends up in the cell.

Downstream

Failure of GATOR1 Recruitment to the Lysosomal Surface The complex's function is to bring GATOR1 to the lysosome, so its disassembly leaves GATOR1 mislocalized.

Show evidence (1 reference)

PMID:28199306 SUPPORT In Vitro

"these results suggest that the four KICSTOR proteins form a large complex in which SZT2 serves as the link between the other three"

Establishes SZT2 as the structural linchpin of the complex.

Failure of GATOR1 Recruitment to the Lysosomal Surface

GATOR1, the GTPase-activating protein for RagA, is no longer brought to the lysosomal membrane and cannot reach its Rag GTPase substrates. This is a localization failure, distinct from the downstream signalling consequence.

lysosomal membrane GO:0005765

Downstream

Loss of Amino-Acid-Sensitive mTORC1 Repression GATOR1 away from the lysosome cannot act on the Rag GTPases that control mTORC1 recruitment.

Show evidence (1 reference)

PMID:28199306 SUPPORT In Vitro

"KICSTOR localizes to lysosomes; binds and recruits GATOR1, but not GATOR2, to the lysosomal surface; and is necessary for the interaction of GATOR1 with its substrates, the Rag GTPases"

Establishes the recruitment function that is lost.

Loss of Amino-Acid-Sensitive mTORC1 Repression

The nutrient-sensing arm that normally switches mTORC1 off during amino-acid or glucose deprivation is broken. This is the loss of a regulatory input; whether mTORC1 is in fact hyperactive is measured separately.

negative regulation of TORC1 signaling GO:1904262 ↓ DECREASED cellular response to amino acid starvation GO:0034198 ⚠ ABNORMAL

Downstream

Constitutive mTORC1 Hyperactivation With the brake removed, mTORC1 stays lysosome-bound and active.

Show evidence (2 references)

PMID:28199306 SUPPORT In Vitro

"is required for amino acid or glucose deprivation to inhibit mTORC1 in cultured human cells"

Names the specific regulatory input that KICSTOR loss abolishes.

PMID:31430354 SUPPORT In Vitro

"Furthermore, patients' LCLs display an excessive response to slight amino acid stimulation."

Shows the sensing arm is disturbed in both directions in patient-derived cells.

Constitutive mTORC1 Hyperactivation

mTORC1 remains at the lysosome and signals regardless of nutrient status. In patient-derived lymphoblastoid cell lines this is measurable as increased S6 kinase and S6 phosphorylation under amino-acid starvation and as constitutive lysosomal mTOR localization. Note the inversion: the causal SZT2 variant is loss of function, but the pathway-level state is gain of function.

TOR signaling GO:0031929 ⇑ GAIN OF FUNCTION

Experimental models

Patient-derived lymphoblastoid cell line CELL LINE Demonstrates the pathway-level consequence directly in patient cells.

Downstream

Excess Outer Radial Glial Cell Production mTORC1 drives amplification of neural stem and progenitor cells in the subventricular zone.

Lowered Intrinsic Seizure Threshold Szt2 loss lowers seizure threshold in mice; the steps between mTORC1 dysregulation and altered excitability are not established.

Show evidence (3 references)

PMID:31430354 SUPPORT In Vitro

"Increased phosphorylation of S6 kinase and S6 was identified in patient-derived cell lines under amino acid-starved condition, suggestive of constitutive hyperactivation of mTORC1 signaling."

Direct biochemical measurement of mTORC1 hyperactivation in patient cells.

PMID:31430354 SUPPORT In Vitro

"This result was validated by constitutive lysosomal localization of mTOR in patients' LCLs."

Independent localization evidence for the same node.

PMID:28199306 SUPPORT Model Organism

"In mice that lack SZT2, mTORC1 signalling is increased in several tissues, including in neurons in the brain."

Confirms the same consequence in neurons in vivo.

Excess Outer Radial Glial Cell Production

In SZT2-mutant human brain organoids the subventricular-zone-like layer contains significantly more outer radial glial cells than control organoids, with mTORC1 activity elevated in that same layer. Outer radial glia are far more abundant in human than in mouse cortex, so this is a human-specific progenitor population.

outer radial glial cell CL:0013000

cell population proliferation GO:0008283 ↑ INCREASED

Experimental models

SZT2-mutant human cerebral brain organoid ORGANOID Provides the only direct evidence that SZT2 loss expands a human-specific cortical progenitor population.

Downstream

Excess Upper-Layer Cortical Neuron Generation Upper-layer neurons generally derive from outer radial glia, so more progenitors yield more of these neurons.

Show evidence (2 references)

PMID:41535455 SUPPORT In Vitro

"found a significantly greater number of outer radial glial cells (oRGCs) in the subventricular zone-like layer (SVZ) of SZT2 mutant (MT) brain organoids compared to control (WT) brain organoids"

Reports the progenitor overproduction directly.

PMID:41535455 SUPPORT In Vitro

"SZT2 MT brain organoids showed higher mTORC1 activity in the SVZ, where neural stem/progenitor cells amplify for cortical expansion in response to mTORC1 activity"

Localizes the elevated mTORC1 activity to the same compartment.

Excess Upper-Layer Cortical Neuron Generation

The number of upper-layer neurons is significantly increased in SZT2-mutant organoids. This is a change in neuronal output that follows from, but is not the same measurement as, the progenitor expansion.

neuron CL:0000540

cerebral cortex development GO:0021987 ⚠ ABNORMAL

Downstream

Brain Overgrowth and Cortical Malformation Excess neuronal production expands the cortex and disturbs its architecture.

Show evidence (1 reference)

PMID:41535455 SUPPORT In Vitro

"The number of upper-layer neurons, which generally originate from oRGCs, was also significantly greater in SZT2 MT brain organoids."

Reports the increased upper-layer neuron count.

Brain Overgrowth and Cortical Malformation

Clinically this appears as macrocephaly with structural anomalies - a thick and short corpus callosum with persistent cavum septum pellucidum, and in the more severely affected, cortical dysplasia and periventricular nodular heterotopia.

cerebral cortex cell migration GO:0021795 ⚠ ABNORMAL

Downstream

Cortical Network Hyperexcitability Dysplastic and heterotopic cortex is intrinsically epileptogenic.

Show evidence (2 references)

PMID:41535455 SUPPORT In Vitro

"Our data suggest that SZT2 dysfunction may cause macrocephaly through dysregulation of mTORC1 in early neural development."

Connects the organoid finding to the macrocephaly phenotype.

PMID:37213690 SUPPORT Human Clinical

"The patients with biallelic null mutations presented severe DEE featured by frequent spasms/tonic seizures and diffuse cortical dysplasia/periventricular nodular heterotopia."

Documents the cortical malformations in the severe genotype group.

Lowered Intrinsic Seizure Threshold

SZT2 was originally identified as a seizure-threshold modifier in mice, where loss of function lowers the threshold for evoked seizures and enhances epileptogenesis. This arm is independent of any structural malformation, which matters because it predicts epilepsy even where imaging is normal.

neuron CL:0000540

Downstream

Cortical Network Hyperexcitability A lowered threshold makes network-level hyperexcitability more likely.

Show evidence (2 references)

PMID:23932106 SUPPORT Model Organism

"Szt2 has been shown to influence seizure threshold and epileptogenesis in mice, consistent with our findings in humans"

States the seizure-threshold role established in mouse genetics.

PMID:37213690 SUPPORT Model Organism

"In mice, heterozygous knock-out of Stz2 led to minimal clonic seizures, while the homozygous knock-out causes caused preweaning lethality with incomplete penetrance and maximal tonic hindlimb extension seizures"

Gives the dose-dependent mouse seizure phenotype.

Cortical Network Hyperexcitability

Cortical networks discharge abnormally, with multifocal epileptiform activity on EEG. Two independent upstream routes converge here - the structural malformation and the intrinsic threshold shift.

neuron CL:0000540

Downstream

Drug-Resistant Early-Onset Epilepsy Sustained hyperexcitability manifests as recurrent, treatment-refractory seizures.

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"Her electroencephalogram was characterized by multifocal epileptiform discharges."

Documents the multifocal electrographic correlate.

Drug-Resistant Early-Onset Epilepsy

Seizures begin in the first months to years of life - median five months in biallelic null genotypes - and include epileptic spasms, tonic seizures, and focal seizures that may evolve to bilateral convulsions. Refractoriness is significantly higher in null than in non-null genotypes.

Downstream

Developmental Delay and Intellectual Disability Early, frequent seizures contribute to developmental impairment.

Show evidence (2 references)

PMID:37213690 SUPPORT Human Clinical

"patients with biallelic null mutations presented significantly higher frequency of refractory seizures and earlier onset age of seizure than those with biallelic non-null mutations"

Establishes the genotype dependence of refractoriness and onset age.

PMID:29696782 SUPPORT Human Clinical

"Her epilepsy was refractory to multiple medications, including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, midazolam, and the ketogenic diet."

Illustrates the breadth of pharmacoresistance in a reported case.

Progressive Loss of Central Myelination

In a subset of individuals, serial imaging documents progressive loss of central myelination rather than a static hypomyelination. This is a separate, non-universal disease arm whose relationship to the mTORC1 defect is not established.

central nervous system myelination GO:0022010 ↓ DECREASED

Downstream

Developmental Delay and Intellectual Disability White-matter loss plausibly contributes to the encephalopathy, though the contribution has not been quantified.

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"Serial imaging characterized the novel finding of progressive loss of central myelination."

Documents the progressive myelin loss on serial imaging.

Developmental Delay and Intellectual Disability

Global developmental delay is the most common presenting feature, with intellectual disability ranging from mild to severe in proportion to residual SZT2 function. A minority of individuals with biallelic missense genotypes have normal neurodevelopment.

Show evidence (2 references)

PMID:37213690 SUPPORT Human Clinical

"The three patients with biallelic missense variants presented mild partial epilepsy with favorable outcomes."

Shows the milder developmental outcome at the hypomorphic end of the spectrum.

PMID:23932106 SUPPORT Human Clinical

"a distinctive early-onset epileptic encephalopathy characterized by refractory epilepsy and absent developmental milestones"

Documents the severe developmental phenotype at the null end.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Head and Neck 1

Macrocephaly HP:0000256

Show evidence (1 reference)

PMID:31430354 SUPPORT Human Clinical

"the main symptoms of which are epilepsy, developmental delay, macrocephaly and a dysmorphic corpus callosum"

Names macrocephaly as a core symptom.

Musculoskeletal 1

Hypotonia HP:0001252

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"macrocephaly (head circumference 51 cm, >2 standard deviations above norm), dysmorphic features (frontal bossing, hypertelorism, microophthalmia, depressed nasal bridge, long-tapered fingers, and hyper-extensible joints), global hypotonia"

Documents global hypotonia in a reported case.

Nervous System 6

Early-Onset Drug-Resistant Epilepsy Seizure HP:0001250

Onset: INFANTILE

Show evidence (1 reference)

PMID:37213690 SUPPORT Human Clinical

"patients with biallelic null mutations presented significantly higher frequency of refractory seizures and earlier onset age of seizure than those with biallelic non-null mutations"

Establishes epilepsy with genotype-dependent refractoriness.

Epileptic Spasms and Tonic Seizures HP:0011097

Onset: INFANTILE

Show evidence (1 reference)

PMID:37213690 SUPPORT Human Clinical

"presented severe DEE featured by frequent spasms/tonic seizures"

Names the seizure semiology in the severe genotype group.

Global Developmental Delay HP:0001263

Show evidence (1 reference)

PMID:23932106 SUPPORT Human Clinical

"refractory epilepsy and absent developmental milestones"

Documents absent developmental milestones in the founding cases.

Periventricular Nodular Heterotopia HP:0032388

Show evidence (1 reference)

PMID:37213690 SUPPORT Human Clinical

"diffuse cortical dysplasia/periventricular nodular heterotopia"

Reports periventricular nodular heterotopia in the null genotype group.

Leukoencephalopathy HP:0002352

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"Serial imaging characterized the novel finding of progressive loss of central myelination."

Documents progressive white-matter involvement.

Developmental Regression HP:0002376

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"by the age of 7, she had lost the ability to communicate, purposefully use her limbs, and was gastrostomy tube dependent"

Documents regression of previously acquired skills.

Other 4

Status Epilepticus HP:0002133

Show evidence (2 references)

PMID:31397114 SUPPORT Human Clinical

"All the individuals were diagnosed as DEEs, drug refractory epilepsy, and experienced status epilepticus (SE); one patient died of SE."

Reports status epilepticus in all three individuals of the series and its contribution to mortality.

PMID:31397114 SUPPORT Human Clinical

"no responses to these antiepileptic drugs (AEDs) were observed and status epilepticus (SE) was predisposed and common"

Records the predisposition to status epilepticus alongside drug refractoriness.

Thick and Short Corpus Callosum Thick corpus callosum HP:0007074

Show evidence (1 reference)

PMID:23932106 SUPPORT Human Clinical

"thick and short corpus callosum and persistent cavum septum pellucidum on brain MRI"

Describes the callosal morphology in the founding cases.

Persistent Cavum Septum Pellucidum HP:0002389

Show evidence (1 reference)

PMID:23932106 SUPPORT Human Clinical

"thick and short corpus callosum and persistent cavum septum pellucidum on brain MRI"

Reports the persistent cavum septum pellucidum.

Cortical Dysplasia HP:0002539

Show evidence (1 reference)

PMID:37213690 SUPPORT Human Clinical

"diffuse cortical dysplasia/periventricular nodular heterotopia"

Reports cortical dysplasia in the null genotype group.

🧬

Genetic Associations

SZT2 (Biallelic pathogenic variants)

Gene: SZT2 hgnc:29040 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:23932106 SUPPORT Human Clinical

"The causative mutations include a homozygous nonsense mutation and a nonsense mutation together with an exonic splice-site mutation in a compound-heterozygous state."

Reports the causal variant classes.

PMID:37213690 SUPPORT Human Clinical

"SZT2 variants were identified in six unrelated cases with heterogeneous epilepsy, including one de novo null variant and five pairs of biallelic variants."

Independent replication and phenotypic spectrum.

💊

Medical Actions

Anti-Seizure Medication

Action: Pharmacotherapy NCIT:C15986

Management is symptomatic. Standard anti-seizure medications are chosen by seizure semiology, with polytherapy common given the high rate of drug resistance; multiple agents including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, and midazolam have failed in reported refractory cases.

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"Her epilepsy was refractory to multiple medications, including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, midazolam, and the ketogenic diet."

Documents failure of conventional pharmacotherapy in a reported case.

Ketogenic Diet

Action: Dietary Intervention NCIT:C15447

Dietary therapy is a standard consideration for drug-resistant paediatric epilepsy. No SZT2-specific outcome data exist, and it failed in at least one reported case.

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"refractory to multiple medications, including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, midazolam, and the ketogenic diet"

In this single reported case the ketogenic diet did not control seizures. One failed case does not establish that the diet is ineffective in the disorder, so this is recorded as partial rather than refuting evidence.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Autosomal recessive counseling with a 25% recurrence risk per pregnancy for carrier parents.

Show evidence (1 reference)

PMID:23932106 SUPPORT Human Clinical

"mutations in SZT2 cause a severe type of autosomal-recessive infantile encephalopathy"

The recessive inheritance that determines the recurrence risk.

🔬

Diagnosis

Molecular Genetic Testing for Biallelic SZT2 Variants (Positive in affected individuals)

Definitive diagnosis rests on identifying two pathogenic SZT2 alleles. Because SZT2 has 71 exons and pathogenic alleles are private, exome or genome sequencing - typically trio-based - rather than single-gene testing is the practical route.

whole exome sequencing NCIT:C101295

Show evidence (2 references)

PMID:23932106 SUPPORT Human Clinical

"Using whole-exome sequencing, we identified biallelic mutations in seizure threshold 2 (SZT2) in both affected children."

Establishes exome sequencing as the route by which the biallelic genotype is identified.

PMID:37213690 SUPPORT Human Clinical

"Trios-based whole-exome sequencing was performed in patients with epilepsy."

Documents the trio-based exome strategy used to ascertain SZT2 cases.

Brain MRI for the Callosal and Cortical Signature

MRI shows a thick and short corpus callosum with a persistent cavum septum pellucidum, described as a relatively distinctive signature, and in the severe genotype group cortical dysplasia and periventricular nodular heterotopia. Serial imaging may show progressive loss of central myelination.

brain magnetic resonance imaging NCIT:C16809

Show evidence (2 references)

PMID:23932106 SUPPORT Human Clinical

"thick and short corpus callosum and persistent cavum septum pellucidum on brain MRI"

Names the characteristic MRI findings.

PMID:29696782 SUPPORT Human Clinical

"Serial imaging characterized the novel finding of progressive loss of central myelination."

Supports serial imaging as the means of detecting the progressive white-matter change.

Electroencephalography

EEG documents the epileptiform substrate; multifocal epileptiform discharges are reported, consistent with the diffuse cortical involvement.

electroencephalography NCIT:C38054

Show evidence (1 reference)

PMID:29696782 SUPPORT Human Clinical

"Her electroencephalogram was characterized by multifocal epileptiform discharges."

Reports the EEG pattern observed in a genetically confirmed case.

🧫

Experimental Models

SZT2-mutant human cerebral brain organoid ORGANOID

CRISPR-edited iPSC-derived cerebral organoids carrying compound heterozygous SZT2 exon-3 deletions, compared against isogenic wild-type organoids.

Publication

PMID:41535455

Pathograph links

Excess Outer Radial Glial Cell Production recapitulates fidelity: moderate Provides the only direct evidence that SZT2 loss expands a human-specific cortical progenitor population.

Limitations: The edited alleles produce in-frame deletions of 28 amino acid residues rather than the truncating variants that predominate in patients, so the model tests a hypomorphic rather than a null allele; and organoids lack the vasculature, microglia, and full laminar maturation of fetal cortex.

Readouts

Outer radial glial cell number in the subventricular-zone-like layer

Direction: INCREASED

Interpretation: SZT2 loss increases the outer radial glial progenitor pool.

Show evidence (1 reference)

PMID:41535455 SUPPORT In Vitro

"a significantly greater number of outer radial glial cells (oRGCs) in the subventricular zone-like layer (SVZ) of SZT2 mutant (MT) brain organoids compared to control (WT) brain organoids"

Reports the quantified progenitor count behind this readout.

Show evidence (1 reference)

PMID:41535455 SUPPORT In Vitro

"Brain organoids derived from induced pluripotent stem cells (iPSCs) are a model which mimics the early stage of neural development in humans"

Justifies the organoid as informative for early human cortical development.

Patient-derived lymphoblastoid cell line CELL_LINE

Epstein-Barr-virus-immortalized lymphoblastoid cell lines from two patients with biallelic SZT2 variants, used to assay mTORC1 activity under amino-acid starvation and stimulation.

Publication

PMID:31430354

Pathograph links

Constitutive mTORC1 Hyperactivation measures fidelity: moderate Demonstrates the pathway-level consequence directly in patient cells.

Limitations: Lymphoblastoid cells are not neurons, so the magnitude of mTORC1 dysregulation in patient brain is inferred rather than measured.

Readouts

S6 kinase and S6 phosphorylation under amino-acid starvation

Direction: INCREASED

Interpretation: mTORC1 output remains high when it should be suppressed.

Show evidence (1 reference)

PMID:31430354 SUPPORT In Vitro

"Increased phosphorylation of S6 kinase and S6 was identified in patient-derived cell lines under amino acid-starved condition"

Reports the biochemical measurement behind this readout.

Show evidence (1 reference)

PMID:31430354 SUPPORT In Vitro

"we aimed to investigate the functional consequence of biallelic SZT2 variants in Epstein-Barr virus-induced lymphoblastoid cell lines (LCLs) established from two patients"

Establishes the model system and its patient provenance.

{ }

Source YAML

click to show

name: SZT2-Related Developmental and Epileptic Encephalopathy
creation_date: "2026-08-19T00:00:00Z"
category: Mendelian
synonyms:
- DEE18
- EIEE18
- epileptic encephalopathy, early infantile, 18
- SZT2-related epileptic encephalopathy
- developmental and epileptic encephalopathy 18
description: >-
  SZT2-related developmental and epileptic encephalopathy (DEE18) is a rare
  autosomal recessive neurodevelopmental disorder caused by biallelic
  loss-of-function variants in SZT2, which encodes the largest subunit of the
  KICSTOR complex (KPTN, ITFG2, C12orf66, SZT2). KICSTOR tethers GATOR1 to the
  lysosomal surface, and it is that tether which allows amino-acid deprivation to
  switch mTORC1 off. Losing SZT2 therefore leaves mTORC1 constitutively
  lysosome-bound and active regardless of nutrient status, placing DEE18 among
  the genetic mTORopathies alongside TSC1/TSC2, DEPDC5, and NPRL2/NPRL3. The core
  clinical picture is early-onset, frequently drug-resistant epilepsy with global
  developmental delay and macrocephaly, characteristically accompanied by a thick
  and short corpus callosum with a persistent cavum septum pellucidum; cortical
  dysplasia, periventricular nodular heterotopia, and in some individuals a
  progressive loss of central myelination are also reported. Severity tracks
  residual SZT2 function: biallelic null genotypes give the severe early-onset
  encephalopathy, whereas biallelic missense genotypes can produce mild partial
  epilepsy with favourable outcome or, in a few individuals, no seizures at all.
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 18
  term:
    id: MONDO:0014201
    label: developmental and epileptic encephalopathy, 18
parents:
- Neurodevelopmental Disorder
- Genetic Disease

inheritance:
- name: Autosomal recessive
  description: >-
    DEE18 requires two pathogenic SZT2 alleles. Both homozygous genotypes, more
    common in consanguineous families, and compound heterozygous genotypes are
    reported.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in SZT2 cause a severe type of autosomal-recessive infantile encephalopathy with intractable seizures and distinct neuroradiological anomalies"
    explanation: >-
      The founding report states the recessive mode of inheritance.

pathophysiology:
- name: Biallelic SZT2 Loss-of-Function Variant
  biological_scale: MOLECULAR
  description: >-
    Two pathogenic SZT2 alleles are present. Most reported alleles are truncating -
    nonsense, frameshift, or canonical splice-site - and are predicted to trigger
    nonsense-mediated decay or premature protein truncation; missense alleles that
    retain partial function are also reported. This node records the genomic lesion
    only.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using whole-exome sequencing, we identified biallelic mutations in seizure threshold 2 (SZT2) in both affected children."
    explanation: >-
      Establishes biallelic SZT2 variants as the causal lesion.
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all three mutations are predicted to result in nonsense-mediated mRNA decay and/or premature protein truncation and thereby loss of SZT2 function"
    explanation: >-
      Characterizes the variant class as loss of function.
  downstream:
  - target: Loss of Functional SZT2 Protein
    causal_link_type: DIRECT
    description: >-
      Truncation or transcript decay removes the SZT2 scaffold protein.

- name: Loss of Functional SZT2 Protein
  biological_scale: MOLECULAR
  description: >-
    The ~380 kDa SZT2 scaffold protein is absent or reduced. SZT2 has no
    enzymatic activity and no strong homology to other proteins; its role is purely
    structural, which is why loss of the protein and loss of the complex are
    distinct steps.
  evidence:
  - reference: PMID:28199306
    reference_title: "KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "four proteins of unknown function encoded by the KPTN, ITFG2, C12orf66, and SZT2 genes and of predicted molecular weights of 48, 49, 50, and 380 kDa, respectively"
    explanation: >-
      Identifies SZT2 as the 380 kDa component of the complex.
  downstream:
  - target: Disassembly of the KICSTOR Complex
    causal_link_type: DIRECT
    description: >-
      SZT2 is the subunit that links the other three components together, so its
      loss dissolves the complex.

- name: Disassembly of the KICSTOR Complex
  biological_scale: MOLECULAR
  description: >-
    Without SZT2 the KPTN-ITFG2 heterodimer and C12orf66 no longer assemble into the
    high-molecular-weight KICSTOR complex. This is a complex-integrity failure,
    upstream of and separable from where GATOR1 ends up in the cell.
  evidence:
  - reference: PMID:28199306
    reference_title: "KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "these results suggest that the four KICSTOR proteins form a large complex in which SZT2 serves as the link between the other three"
    explanation: >-
      Establishes SZT2 as the structural linchpin of the complex.
  downstream:
  - target: Failure of GATOR1 Recruitment to the Lysosomal Surface
    causal_link_type: DIRECT
    description: >-
      The complex's function is to bring GATOR1 to the lysosome, so its disassembly
      leaves GATOR1 mislocalized.

- name: Failure of GATOR1 Recruitment to the Lysosomal Surface
  biological_scale: MOLECULAR
  description: >-
    GATOR1, the GTPase-activating protein for RagA, is no longer brought to the
    lysosomal membrane and cannot reach its Rag GTPase substrates. This is a
    localization failure, distinct from the downstream signalling consequence.
  cellular_components:
  - preferred_term: lysosomal membrane
    term:
      id: GO:0005765
      label: lysosomal membrane
  evidence:
  - reference: PMID:28199306
    reference_title: "KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "KICSTOR localizes to lysosomes; binds and recruits GATOR1, but not GATOR2, to the lysosomal surface; and is necessary for the interaction of GATOR1 with its substrates, the Rag GTPases"
    explanation: >-
      Establishes the recruitment function that is lost.
  downstream:
  - target: Loss of Amino-Acid-Sensitive mTORC1 Repression
    causal_link_type: DIRECT
    description: >-
      GATOR1 away from the lysosome cannot act on the Rag GTPases that control
      mTORC1 recruitment.

- name: Loss of Amino-Acid-Sensitive mTORC1 Repression
  biological_scale: MOLECULAR
  description: >-
    The nutrient-sensing arm that normally switches mTORC1 off during amino-acid or
    glucose deprivation is broken. This is the loss of a regulatory input; whether
    mTORC1 is in fact hyperactive is measured separately.
  biological_processes:
  - preferred_term: negative regulation of TORC1 signaling
    term:
      id: GO:1904262
      label: negative regulation of TORC1 signaling
    modifier: DECREASED
  - preferred_term: cellular response to amino acid starvation
    term:
      id: GO:0034198
      label: cellular response to amino acid starvation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:28199306
    reference_title: "KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "is required for amino acid or glucose deprivation to inhibit mTORC1 in cultured human cells"
    explanation: >-
      Names the specific regulatory input that KICSTOR loss abolishes.
  - reference: PMID:31430354
    reference_title: "Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, patients' LCLs display an excessive response to slight amino acid stimulation."
    explanation: >-
      Shows the sensing arm is disturbed in both directions in patient-derived cells.
  downstream:
  - target: Constitutive mTORC1 Hyperactivation
    causal_link_type: DIRECT
    description: >-
      With the brake removed, mTORC1 stays lysosome-bound and active.

- name: Constitutive mTORC1 Hyperactivation
  biological_scale: MOLECULAR
  description: >-
    mTORC1 remains at the lysosome and signals regardless of nutrient status. In
    patient-derived lymphoblastoid cell lines this is measurable as increased S6
    kinase and S6 phosphorylation under amino-acid starvation and as constitutive
    lysosomal mTOR localization. Note the inversion: the causal SZT2 variant is loss
    of function, but the pathway-level state is gain of function.
  biological_processes:
  - preferred_term: TOR signaling
    term:
      id: GO:0031929
      label: TOR signaling
    modifier: GAIN_OF_FUNCTION
  evidence:
  - reference: PMID:31430354
    reference_title: "Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Increased phosphorylation of S6 kinase and S6 was identified in patient-derived cell lines under amino acid-starved condition, suggestive of constitutive hyperactivation of mTORC1 signaling."
    explanation: >-
      Direct biochemical measurement of mTORC1 hyperactivation in patient cells.
  - reference: PMID:31430354
    reference_title: "Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This result was validated by constitutive lysosomal localization of mTOR in patients' LCLs."
    explanation: >-
      Independent localization evidence for the same node.
  - reference: PMID:28199306
    reference_title: "KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In mice that lack SZT2, mTORC1 signalling is increased in several tissues, including in neurons in the brain."
    explanation: >-
      Confirms the same consequence in neurons in vivo.
  downstream:
  - target: Excess Outer Radial Glial Cell Production
    causal_link_type: DIRECT
    description: >-
      mTORC1 drives amplification of neural stem and progenitor cells in the
      subventricular zone.
  - target: Lowered Intrinsic Seizure Threshold
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Szt2 loss lowers seizure threshold in mice; the steps between mTORC1
      dysregulation and altered excitability are not established.

- name: Excess Outer Radial Glial Cell Production
  biological_scale: CELLULAR
  description: >-
    In SZT2-mutant human brain organoids the subventricular-zone-like layer contains
    significantly more outer radial glial cells than control organoids, with mTORC1
    activity elevated in that same layer. Outer radial glia are far more abundant in
    human than in mouse cortex, so this is a human-specific progenitor population.
  cell_types:
  - preferred_term: outer radial glial cell
    term:
      id: CL:0013000
      label: forebrain radial glial cell
  biological_processes:
  - preferred_term: cell population proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
    modifier: INCREASED
  evidence:
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "found a significantly greater number of outer radial glial cells (oRGCs) in the subventricular zone-like layer (SVZ) of SZT2 mutant (MT) brain organoids compared to control (WT) brain organoids"
    explanation: >-
      Reports the progenitor overproduction directly.
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SZT2 MT brain organoids showed higher mTORC1 activity in the SVZ, where neural stem/progenitor cells amplify for cortical expansion in response to mTORC1 activity"
    explanation: >-
      Localizes the elevated mTORC1 activity to the same compartment.
  downstream:
  - target: Excess Upper-Layer Cortical Neuron Generation
    causal_link_type: DIRECT
    description: >-
      Upper-layer neurons generally derive from outer radial glia, so more
      progenitors yield more of these neurons.

- name: Excess Upper-Layer Cortical Neuron Generation
  biological_scale: TISSUE
  description: >-
    The number of upper-layer neurons is significantly increased in SZT2-mutant
    organoids. This is a change in neuronal output that follows from, but is not the
    same measurement as, the progenitor expansion.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: cerebral cortex development
    term:
      id: GO:0021987
      label: cerebral cortex development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The number of upper-layer neurons, which generally originate from oRGCs, was also significantly greater in SZT2 MT brain organoids."
    explanation: >-
      Reports the increased upper-layer neuron count.
  downstream:
  - target: Brain Overgrowth and Cortical Malformation
    causal_link_type: DIRECT
    description: >-
      Excess neuronal production expands the cortex and disturbs its architecture.

- name: Brain Overgrowth and Cortical Malformation
  biological_scale: ORGANISM
  description: >-
    Clinically this appears as macrocephaly with structural anomalies - a thick and
    short corpus callosum with persistent cavum septum pellucidum, and in the more
    severely affected, cortical dysplasia and periventricular nodular heterotopia.
  biological_processes:
  - preferred_term: cerebral cortex cell migration
    term:
      id: GO:0021795
      label: cerebral cortex cell migration
    modifier: ABNORMAL
  evidence:
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our data suggest that SZT2 dysfunction may cause macrocephaly through dysregulation of mTORC1 in early neural development."
    explanation: >-
      Connects the organoid finding to the macrocephaly phenotype.
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients with biallelic null mutations presented severe DEE featured by frequent spasms/tonic seizures and diffuse cortical dysplasia/periventricular nodular heterotopia."
    explanation: >-
      Documents the cortical malformations in the severe genotype group.
  downstream:
  - target: Cortical Network Hyperexcitability
    causal_link_type: DIRECT
    description: >-
      Dysplastic and heterotopic cortex is intrinsically epileptogenic.

- name: Lowered Intrinsic Seizure Threshold
  biological_scale: TISSUE
  description: >-
    SZT2 was originally identified as a seizure-threshold modifier in mice, where
    loss of function lowers the threshold for evoked seizures and enhances
    epileptogenesis. This arm is independent of any structural malformation, which
    matters because it predicts epilepsy even where imaging is normal.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Szt2 has been shown to influence seizure threshold and epileptogenesis in mice, consistent with our findings in humans"
    explanation: >-
      States the seizure-threshold role established in mouse genetics.
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In mice, heterozygous knock-out of Stz2 led to minimal clonic seizures, while the homozygous knock-out causes caused preweaning lethality with incomplete penetrance and maximal tonic hindlimb extension seizures"
    explanation: >-
      Gives the dose-dependent mouse seizure phenotype.
  downstream:
  - target: Cortical Network Hyperexcitability
    causal_link_type: DIRECT
    description: >-
      A lowered threshold makes network-level hyperexcitability more likely.

- name: Cortical Network Hyperexcitability
  biological_scale: TISSUE
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  description: >-
    Cortical networks discharge abnormally, with multifocal epileptiform activity on
    EEG. Two independent upstream routes converge here - the structural malformation
    and the intrinsic threshold shift.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her electroencephalogram was characterized by multifocal epileptiform discharges."
    explanation: >-
      Documents the multifocal electrographic correlate.
  downstream:
  - target: Drug-Resistant Early-Onset Epilepsy
    causal_link_type: DIRECT
    description: >-
      Sustained hyperexcitability manifests as recurrent, treatment-refractory seizures.

- name: Drug-Resistant Early-Onset Epilepsy
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  description: >-
    Seizures begin in the first months to years of life - median five months in
    biallelic null genotypes - and include epileptic spasms, tonic seizures, and
    focal seizures that may evolve to bilateral convulsions. Refractoriness is
    significantly higher in null than in non-null genotypes.
  evidence:
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with biallelic null mutations presented significantly higher frequency of refractory seizures and earlier onset age of seizure than those with biallelic non-null mutations"
    explanation: >-
      Establishes the genotype dependence of refractoriness and onset age.
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her epilepsy was refractory to multiple medications, including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, midazolam, and the ketogenic diet."
    explanation: >-
      Illustrates the breadth of pharmacoresistance in a reported case.
  downstream:
  - target: Developmental Delay and Intellectual Disability
    causal_link_type: DIRECT
    description: >-
      Early, frequent seizures contribute to developmental impairment.

- name: Progressive Loss of Central Myelination
  biological_scale: TISSUE
  description: >-
    In a subset of individuals, serial imaging documents progressive loss of central
    myelination rather than a static hypomyelination. This is a separate,
    non-universal disease arm whose relationship to the mTORC1 defect is not
    established.
  biological_processes:
  - preferred_term: central nervous system myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serial imaging characterized the novel finding of progressive loss of central myelination."
    explanation: >-
      Documents the progressive myelin loss on serial imaging.
  downstream:
  - target: Developmental Delay and Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      White-matter loss plausibly contributes to the encephalopathy, though the
      contribution has not been quantified.

- name: Developmental Delay and Intellectual Disability
  biological_scale: ORGANISM
  description: >-
    Global developmental delay is the most common presenting feature, with
    intellectual disability ranging from mild to severe in proportion to residual
    SZT2 function. A minority of individuals with biallelic missense genotypes have
    normal neurodevelopment.
  evidence:
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The three patients with biallelic missense variants presented mild partial epilepsy with favorable outcomes."
    explanation: >-
      Shows the milder developmental outcome at the hypomorphic end of the spectrum.
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a distinctive early-onset epileptic encephalopathy characterized by refractory epilepsy and absent developmental milestones"
    explanation: >-
      Documents the severe developmental phenotype at the null end.

phenotypes:
- category: Neurological
  name: Early-Onset Drug-Resistant Epilepsy
  description: >-
    Seizures beginning in infancy or early childhood, frequently refractory to
    multiple anti-seizure medications; median onset five months in biallelic null
    genotypes.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: INFANTILE
      notes: >-
        Median seizure onset five months in biallelic null genotypes, twelve months
        with one null allele, and thirty-six months in biallelic non-null genotypes,
        so onset spans infancy into early childhood by genotype.
  evidence:
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with biallelic null mutations presented significantly higher frequency of refractory seizures and earlier onset age of seizure than those with biallelic non-null mutations"
    explanation: >-
      Establishes epilepsy with genotype-dependent refractoriness.
- category: Neurological
  name: Epileptic Spasms and Tonic Seizures
  description: >-
    Frequent spasms and tonic seizures characterize the severe biallelic-null group.
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented severe DEE featured by frequent spasms/tonic seizures"
    explanation: >-
      Names the seizure semiology in the severe genotype group.
- category: Neurological
  name: Status Epilepticus
  description: >-
    High susceptibility to status epilepticus is a clinically important complication.
    All three individuals in one reported series experienced status epilepticus, and
    one died of it. Note this is generic status epilepticus, not specifically the
    myoclonic subtype.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:31397114
    reference_title: "Novel SZT2 mutations in three patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All the individuals were diagnosed as DEEs, drug refractory epilepsy, and experienced status epilepticus (SE); one patient died of SE."
    explanation: >-
      Reports status epilepticus in all three individuals of the series and its
      contribution to mortality.
  - reference: PMID:31397114
    reference_title: "Novel SZT2 mutations in three patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "no responses to these antiepileptic drugs (AEDs) were observed and status epilepticus (SE) was predisposed and common"
    explanation: >-
      Records the predisposition to status epilepticus alongside drug refractoriness.
- category: Neurological
  name: Global Developmental Delay
  description: >-
    The most common presenting feature across reported cohorts.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "refractory epilepsy and absent developmental milestones"
    explanation: >-
      Documents absent developmental milestones in the founding cases.
- category: Neurological
  name: Macrocephaly
  description: >-
    Enlarged head circumference, a near-defining feature and the clinical counterpart
    of the mTORC1-driven progenitor expansion.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:31430354
    reference_title: "Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the main symptoms of which are epilepsy, developmental delay, macrocephaly and a dysmorphic corpus callosum"
    explanation: >-
      Names macrocephaly as a core symptom.
- category: Neurological
  name: Thick and Short Corpus Callosum
  description: >-
    A thick, short corpus callosum, described as a relatively distinctive MRI
    signature of this disorder.
  phenotype_term:
    preferred_term: Thick corpus callosum
    term:
      id: HP:0007074
      label: Thick corpus callosum
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thick and short corpus callosum and persistent cavum septum pellucidum on brain MRI"
    explanation: >-
      Describes the callosal morphology in the founding cases.
- category: Neurological
  name: Persistent Cavum Septum Pellucidum
  description: >-
    A persistent cavum septum pellucidum accompanies the callosal anomaly.
  phenotype_term:
    preferred_term: Cavum septum pellucidum
    term:
      id: HP:0002389
      label: Cavum septum pellucidum
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thick and short corpus callosum and persistent cavum septum pellucidum on brain MRI"
    explanation: >-
      Reports the persistent cavum septum pellucidum.
- category: Neurological
  name: Cortical Dysplasia
  description: >-
    Diffuse cortical dysplasia, reported in the severe biallelic-null group.
  phenotype_term:
    preferred_term: Cortical dysplasia
    term:
      id: HP:0002539
      label: Cortical dysplasia
  evidence:
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diffuse cortical dysplasia/periventricular nodular heterotopia"
    explanation: >-
      Reports cortical dysplasia in the null genotype group.
- category: Neurological
  name: Periventricular Nodular Heterotopia
  description: >-
    Nodular grey-matter heterotopia lining the ventricles, reported alongside cortical
    dysplasia in the severe group.
  phenotype_term:
    preferred_term: Periventricular nodular heterotopia
    term:
      id: HP:0032388
      label: Periventricular nodular heterotopia
  evidence:
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diffuse cortical dysplasia/periventricular nodular heterotopia"
    explanation: >-
      Reports periventricular nodular heterotopia in the null genotype group.
- category: Neurological
  name: Leukoencephalopathy
  description: >-
    Progressive loss of central myelination documented on serial imaging in a subset
    of individuals.
  phenotype_term:
    preferred_term: Leukoencephalopathy
    term:
      id: HP:0002352
      label: Leukoencephalopathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serial imaging characterized the novel finding of progressive loss of central myelination."
    explanation: >-
      Documents progressive white-matter involvement.
- category: Neurological
  name: Hypotonia
  description: >-
    Global hypotonia, reported in a substantial minority of individuals.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "macrocephaly (head circumference 51 cm, >2 standard deviations above norm), dysmorphic features (frontal bossing, hypertelorism, microophthalmia, depressed nasal bridge, long-tapered fingers, and hyper-extensible joints), global hypotonia"
    explanation: >-
      Documents global hypotonia in a reported case.
- category: Neurological
  name: Developmental Regression
  description: >-
    Psychomotor regression, with loss of communication and purposeful limb use
    reported in the progressive end of the spectrum.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "by the age of 7, she had lost the ability to communicate, purposefully use her limbs, and was gastrostomy tube dependent"
    explanation: >-
      Documents regression of previously acquired skills.

genetic:
- name: SZT2
  association: Biallelic pathogenic variants
  presence: Positive
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    SZT2 (chromosome 1p34.2, 71 exons) encodes the ~380 kDa scaffold subunit of the
    KICSTOR complex. Pathogenic alleles are predominantly truncating - nonsense,
    frameshift, and canonical splice-site - with missense alleles retaining partial
    function and producing milder phenotypes. Severity tracks residual function:
    biallelic null genotypes give severe DEE, biallelic missense genotypes mild
    partial epilepsy with favourable outcome.
  gene_term:
    preferred_term: SZT2
    term:
      id: hgnc:29040
      label: SZT2
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The causative mutations include a homozygous nonsense mutation and a nonsense mutation together with an exonic splice-site mutation in a compound-heterozygous state."
    explanation: >-
      Reports the causal variant classes.
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SZT2 variants were identified in six unrelated cases with heterogeneous epilepsy, including one de novo null variant and five pairs of biallelic variants."
    explanation: >-
      Independent replication and phenotypic spectrum.

diagnosis:
- name: Molecular Genetic Testing for Biallelic SZT2 Variants
  description: >-
    Definitive diagnosis rests on identifying two pathogenic SZT2 alleles. Because
    SZT2 has 71 exons and pathogenic alleles are private, exome or genome sequencing
    - typically trio-based - rather than single-gene testing is the practical route.
  diagnosis_term:
    preferred_term: whole exome sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  presence: Positive in affected individuals
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using whole-exome sequencing, we identified biallelic mutations in seizure threshold 2 (SZT2) in both affected children."
    explanation: >-
      Establishes exome sequencing as the route by which the biallelic genotype is
      identified.
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Trios-based whole-exome sequencing was performed in patients with epilepsy."
    explanation: >-
      Documents the trio-based exome strategy used to ascertain SZT2 cases.
- name: Brain MRI for the Callosal and Cortical Signature
  description: >-
    MRI shows a thick and short corpus callosum with a persistent cavum septum
    pellucidum, described as a relatively distinctive signature, and in the severe
    genotype group cortical dysplasia and periventricular nodular heterotopia.
    Serial imaging may show progressive loss of central myelination.
  diagnosis_term:
    preferred_term: brain magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thick and short corpus callosum and persistent cavum septum pellucidum on brain MRI"
    explanation: >-
      Names the characteristic MRI findings.
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serial imaging characterized the novel finding of progressive loss of central myelination."
    explanation: >-
      Supports serial imaging as the means of detecting the progressive white-matter
      change.
- name: Electroencephalography
  description: >-
    EEG documents the epileptiform substrate; multifocal epileptiform discharges are
    reported, consistent with the diffuse cortical involvement.
  diagnosis_term:
    preferred_term: electroencephalography
    term:
      id: NCIT:C38054
      label: Electroencephalography
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her electroencephalogram was characterized by multifocal epileptiform discharges."
    explanation: >-
      Reports the EEG pattern observed in a genetically confirmed case.

treatments:
- name: Anti-Seizure Medication
  description: >-
    Management is symptomatic. Standard anti-seizure medications are chosen by
    seizure semiology, with polytherapy common given the high rate of drug
    resistance; multiple agents including lamotrigine, levetiracetam, phenytoin,
    phenobarbital, topiramate, rufinamide, and midazolam have failed in reported
    refractory cases.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her epilepsy was refractory to multiple medications, including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, midazolam, and the ketogenic diet."
    explanation: >-
      Documents failure of conventional pharmacotherapy in a reported case.
- name: Ketogenic Diet
  description: >-
    Dietary therapy is a standard consideration for drug-resistant paediatric
    epilepsy. No SZT2-specific outcome data exist, and it failed in at least one
    reported case.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Dietary Intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "refractory to multiple medications, including lamotrigine, levetiracetam, phenytoin, phenobarbital, topiramate, rufinamide, midazolam, and the ketogenic diet"
    explanation: >-
      In this single reported case the ketogenic diet did not control seizures. One
      failed case does not establish that the diet is ineffective in the disorder, so
      this is recorded as partial rather than refuting evidence.
- name: Genetic Counseling
  description: >-
    Autosomal recessive counseling with a 25% recurrence risk per pregnancy for
    carrier parents.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutations in SZT2 cause a severe type of autosomal-recessive infantile encephalopathy"
    explanation: >-
      The recessive inheritance that determines the recurrence risk.

experimental_models:
- name: SZT2-mutant human cerebral brain organoid
  experimental_model_type: ORGANOID
  description: >-
    CRISPR-edited iPSC-derived cerebral organoids carrying compound heterozygous
    SZT2 exon-3 deletions, compared against isogenic wild-type organoids.
  publication: PMID:41535455
  modeled_mechanisms:
  - target: Excess Outer Radial Glial Cell Production
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Provides the only direct evidence that SZT2 loss expands a human-specific
      cortical progenitor population.
    limitations: >-
      The edited alleles produce in-frame deletions of 28 amino acid residues rather
      than the truncating variants that predominate in patients, so the model tests a
      hypomorphic rather than a null allele; and organoids lack the vasculature,
      microglia, and full laminar maturation of fetal cortex.
    readouts:
    - name: Outer radial glial cell number in the subventricular-zone-like layer
      target: Excess Outer Radial Glial Cell Production
      direction: INCREASED
      interpretation: >-
        SZT2 loss increases the outer radial glial progenitor pool.
      evidence:
      - reference: PMID:41535455
        reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "a significantly greater number of outer radial glial cells (oRGCs) in the subventricular zone-like layer (SVZ) of SZT2 mutant (MT) brain organoids compared to control (WT) brain organoids"
        explanation: >-
          Reports the quantified progenitor count behind this readout.
    evidence:
    - reference: PMID:41535455
      reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Brain organoids derived from induced pluripotent stem cells (iPSCs) are a model which mimics the early stage of neural development in humans"
      explanation: >-
        Justifies the organoid as informative for early human cortical development.
- name: Patient-derived lymphoblastoid cell line
  experimental_model_type: CELL_LINE
  description: >-
    Epstein-Barr-virus-immortalized lymphoblastoid cell lines from two patients with
    biallelic SZT2 variants, used to assay mTORC1 activity under amino-acid
    starvation and stimulation.
  publication: PMID:31430354
  modeled_mechanisms:
  - target: Constitutive mTORC1 Hyperactivation
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      Demonstrates the pathway-level consequence directly in patient cells.
    limitations: >-
      Lymphoblastoid cells are not neurons, so the magnitude of mTORC1 dysregulation
      in patient brain is inferred rather than measured.
    readouts:
    - name: S6 kinase and S6 phosphorylation under amino-acid starvation
      target: Constitutive mTORC1 Hyperactivation
      direction: INCREASED
      interpretation: >-
        mTORC1 output remains high when it should be suppressed.
      evidence:
      - reference: PMID:31430354
        reference_title: "Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Increased phosphorylation of S6 kinase and S6 was identified in patient-derived cell lines under amino acid-starved condition"
        explanation: >-
          Reports the biochemical measurement behind this readout.
    evidence:
    - reference: PMID:31430354
      reference_title: "Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we aimed to investigate the functional consequence of biallelic SZT2 variants in Epstein-Barr virus-induced lymphoblastoid cell lines (LCLs) established from two patients"
      explanation: >-
        Establishes the model system and its patient provenance.

discussions:
- discussion_id: gap_mtor_inhibitor_repurposing_in_szt2
  prompt: >-
    Would mTOR inhibition with sirolimus or everolimus, effective in other genetic
    mTORopathies, reduce seizure burden in SZT2-related DEE, and would any benefit
    require treatment before the progenitor-expansion window has closed?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Constitutive mTORC1 Hyperactivation
  - pathophysiology#Excess Outer Radial Glial Cell Production
  rationale: >-
    The mechanism converges on constitutive mTORC1 hyperactivation, the same node
    that mTOR inhibitors target in tuberous sclerosis complex, so repurposing is
    biologically motivated. No published clinical trial or treated case series exists
    for SZT2. The timing question is the substantive one: the organoid data place a
    large part of the pathology in progenitor amplification during early cortical
    development, which is complete long before a genetic diagnosis is typically made.
    If the macrocephaly and cortical malformation are developmentally fixed, an mTOR
    inhibitor started postnatally could at best address the residual excitability arm,
    and a trial designed around structural or head-circumference endpoints would be
    measuring the wrong thing.
  evidence:
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our data suggest that SZT2 dysfunction may cause macrocephaly through dysregulation of mTORC1 in early neural development."
    explanation: >-
      Places the progenitor mechanism in early development, which is what creates the
      therapeutic-window problem.
  - reference: PMID:28199306
    reference_title: "KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "several KICSTOR components are mutated in neurological diseases associated with mutations that lead to hyperactive mTORC1 signalling"
    explanation: >-
      Places SZT2 in the mTORopathy family whose therapy is being considered for reuse.
  proposed_experiments:
  - experiment_id: exp_rapamycin_timing_window_organoid
    name: Rapamycin rescue as a function of treatment onset in SZT2-mutant organoids
    description: >-
      Treat SZT2-mutant cerebral organoids with rapamycin starting at successively
      later stages of organoid development and score outer radial glial cell number,
      upper-layer neuron number, and mTORC1 activity, to establish whether the
      progenitor phenotype remains correctable once cortical expansion is underway.

- discussion_id: gap_seizure_threshold_arm_independent_of_malformation
  prompt: >-
    Does SZT2 loss lower neuronal excitability threshold directly, or is the epilepsy
    entirely secondary to the cortical malformation produced by mTORC1-driven
    progenitor expansion?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Lowered Intrinsic Seizure Threshold
  - pathophysiology#Brain Overgrowth and Cortical Malformation
  rationale: >-
    Two arms converge on hyperexcitability in this model. The malformation arm is
    well evidenced in human imaging and organoids. The intrinsic-threshold arm rests
    on mouse genetics - Szt2 was named for its effect on seizure threshold - and no
    study has isolated it from structural change in a mammalian brain. The
    distinction is testable and consequential: individuals with biallelic missense
    genotypes can have epilepsy without the severe malformations, which is difficult
    to explain if malformation were the whole story, but that observation is
    confounded because milder genotypes also produce milder structural change. If the
    intrinsic arm is real, seizure control would not require reversing a structural
    abnormality.
  evidence:
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Although the molecular role of the peroxisomal protein SZT2 in neuronal excitability and brain development remains to be defined, Szt2 has been shown to influence seizure threshold and epileptogenesis in mice"
    explanation: >-
      States both the seizure-threshold finding and that its molecular basis is
      undefined.
  - reference: PMID:37213690
    reference_title: "SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study suggested that SZT2 variants were potentially associated with partial epilepsy with favorable outcomes without NDD, expanding the phenotypic spectrum of SZT2."
    explanation: >-
      Documents epilepsy occurring without neurodevelopmental abnormality, which is
      the human observation that motivates a malformation-independent arm.
  proposed_experiments:
  - experiment_id: exp_adult_onset_szt2_deletion_excitability
    name: Excitability after adult-onset conditional Szt2 deletion
    description: >-
      Delete Szt2 conditionally in adult mouse forebrain neurons, after cortical
      development is complete, and measure seizure threshold to pentylenetetrazol and
      kindling rate alongside histology, to test whether excitability changes arise in
      the absence of any developmental malformation.

- discussion_id: mismatch_organoid_hypomorph_versus_patient_null
  prompt: >-
    Does the SZT2 brain-organoid model, which carries in-frame 28-residue deletions
    rather than the truncating variants that predominate in patients, report the
    same lesion as human biallelic-null disease, and are outer radial glia the right
    cell type to carry the mechanism given their scarcity in the mouse models that
    established the seizure-threshold arm?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Excess Outer Radial Glial Cell Production
  - pathophysiology#Excess Upper-Layer Cortical Neuron Generation
  rationale: >-
    The organoid study is the only model of the human cortical mechanism, and it is a
    genuine advance precisely because outer radial glia are far more abundant in human
    than in mouse cortex - so the mouse literature that established the
    seizure-threshold arm structurally cannot address this branch. But the CRISPR
    alleles used are in-frame deletions of 28 residues at the distal end of exon 3,
    described by the authors as of uncertain functional impact, whereas most patient
    alleles are predicted null. A hypomorph in a human model and a null in a mouse
    model between them leave the human null cortical phenotype uninterrogated, so the
    magnitude of progenitor expansion in patient brain remains an extrapolation.
  evidence:
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the introduced mutations result in in-frame deletions of 84 bp (28 amino acid residues), corresponding to the distal portion of exon 3"
    explanation: >-
      Documents that the model allele is an in-frame deletion, not a truncating null.
  - reference: PMID:41535455
    reference_title: "Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "oRGCs are more abundant in humans than in mice, and contribute to the expansion of the human brain by differentiating into upper-layer neurons"
    explanation: >-
      States the species difference that makes mouse models unable to test this arm.
  - reference: PMID:23932106
    reference_title: "Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all three mutations are predicted to result in nonsense-mediated mRNA decay and/or premature protein truncation"
    explanation: >-
      Establishes that patient alleles are typically null, unlike the model allele.
  proposed_experiments:
  - experiment_id: exp_isogenic_null_versus_inframe_organoids
    name: Isogenic null versus in-frame-deletion SZT2 organoid comparison
    description: >-
      Generate isogenic organoid lines carrying a truncating SZT2 null allele
      alongside the published in-frame deletion, and compare mTORC1 activity, outer
      radial glial number, and upper-layer neuron number, to establish whether the
      published phenotype under-reports the human null lesion.

- discussion_id: gap_leukoencephalopathy_relationship_to_mtorc1
  prompt: >-
    Is the progressive loss of central myelination reported in some individuals with
    SZT2-related DEE a consequence of mTORC1 dysregulation in oligodendroglia, a
    consequence of sustained seizure burden, or an unrelated feature of the severe
    end of the spectrum?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Progressive Loss of Central Myelination
  rationale: >-
    Progressive myelin loss is documented on serial imaging but is not universal, and
    the mechanistic account curated here stops at the observation. mTORC1 has
    well-established roles in oligodendrocyte differentiation and myelination, so a
    direct route is plausible, but so is a seizure-burden explanation, and the single
    detailed case had a complex terminal course. Nothing in the published literature
    separates these. The distinction matters for prognosis: a directly
    mTORC1-dependent myelin phenotype would be a candidate target for mTOR
    inhibition, whereas a seizure-driven one would not.
  evidence:
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This case expands our clinical understanding of the SZT2-phenotype and emphasizes the role of this gene in the diagnostic investigation for EOEE and leukoencephalopathies."
    explanation: >-
      Establishes the white-matter phenotype while leaving its mechanism open.
  - reference: PMID:29696782
    reference_title: "Mutations in SZT2 result in early-onset epileptic encephalopathy and leukoencephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reported imaging findings include atrophy and dysgenesis of the corpus callosum"
    explanation: >-
      Prior imaging reports describe callosal change but not progressive myelin loss,
      underlining that this feature is neither universal nor mechanistically explained.
  proposed_experiments:
  - experiment_id: exp_oligodendrocyte_specific_szt2_deletion
    name: Oligodendrocyte-lineage-restricted Szt2 deletion and myelination
    description: >-
      Delete Szt2 selectively in the oligodendrocyte lineage in mice, in the absence
      of neuronal deletion and therefore of seizures, and quantify myelin thickness,
      oligodendrocyte maturation markers, and mTORC1 activity over time to test
      whether myelin loss is cell-autonomous to the oligodendrocyte lineage.

datasets: []

📚

References & Deep Research

Deep Research

Claude Code ▸

SZT2-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 19 citations 2026-08-19T13:25:33.261076

SZT2-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

1. Disease Information

Overview. SZT2-Related Developmental and Epileptic Encephalopathy (also designated Developmental and Epileptic Encephalopathy 18, DEE18; historically "epileptic encephalopathy, early infantile, 18" / EIEE18) is a rare, autosomal recessive neurodevelopmental disorder caused by biallelic pathogenic variants in SZT2 (seizure threshold 2 homolog). The core clinical triad is early-onset, often drug-resistant epilepsy; global developmental delay/intellectual disability; and macrocephaly, frequently accompanied by a dysmorphic (thick/short) corpus callosum, cortical malformations (cortical dysplasia, periventricular nodular heterotopia), and in some patients progressive white-matter (leukoencephalopathy) changes. Mechanistically, SZT2 is a scaffolding subunit of the KICSTOR complex, which represses mTORC1 signaling under amino-acid-limited conditions; loss-of-function SZT2 variants cause constitutive mTORC1 hyperactivation, placing this disorder within the growing family of genetic mTORopathies (Basel-Vanagaite et al. 2013, PMID:23932106; Wolfson et al. 2017, PMID:28199306).

Key identifiers: - OMIM phenotype: 615476 (Developmental and Epileptic Encephalopathy 18); OMIM gene: SZT2, 615463 - Gene location: chromosome 1p34.2; 71–72 exons; encodes a ~378 kDa scaffold protein with no strong homology to other proteins - HGNC: SZT2 (HGNC:29175) - Synonyms for the gene/protein: KIAA0467; seizure threshold 2 protein homolog - Disease synonyms: Epileptic encephalopathy, early infantile, 18 (EIEE18); DEE18; SZT2-related epilepsy/encephalopathy; SZT2 deficiency disorder - Inheritance: Autosomal recessive

Data provenance. Nearly all available information derives from aggregated case reports and small case series (individual patients and sibships identified by exome/genome sequencing or epilepsy gene panels), pooled in several systematic literature reviews (e.g., 41–50 cumulative published patients as of 2023), rather than large prospective cohorts or population-level EHR resources — consistent with this being an ultra-rare condition.

Sources: - Novel SZT2 mutations in three patients with developmental and epileptic encephalopathies (PMC6732301) - SZT2 variants associated with partial epilepsy or epileptic encephalopathy and the genotype-phenotype correlation (PMC10198435, PMID:37213690) - Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 (PLOS ONE, PMC6701784) - Developmental and epileptic encephalopathy due to SZT2 genomic variants (PubMed PMID:32402703) - Biallelic SZT2 Mutations Cause Infantile Encephalopathy with Epilepsy and Dysmorphic Corpus Callosum (AJHG, PMID:23932106) - KICSTOR recruits GATOR1 to the lysosome (Nature, PMID:28199306)

2. Etiology

Disease causal factors. SZT2-related DEE18 is a purely monogenic (Mendelian) disorder: biallelic (homozygous or compound heterozygous) pathogenic variants in SZT2, inherited from unaffected heterozygous carrier parents. There is no known environmental or infectious cause of the underlying genetic lesion, though the epilepsy phenotype (like most genetic epilepsies) can be modulated by febrile illness or other seizure precipitants in affected individuals.

Genetic risk factors: - Causal variants: Predominantly loss-of-function alleles — nonsense, frameshift, canonical splice-site, and large deletions — distributed across the gene's 71 exons, with truncating ("null") variants comprising the majority of reported pathogenic alleles. Missense ("non-null") variants are also reported and tend to retain partial protein function. - Zygosity: Both homozygous (more common in consanguineous families) and compound heterozygous genotypes are reported. A 2023 literature review found 43 cumulative cases: 15 homozygous and 28 compound heterozygous (ScienceDirect case report/review, 2023). - Founder variants: A dedicated variant-classification study identified a founder SZT2 variant in an epilepsy cohort, underscoring population-specific enrichment of certain alleles (bioRxiv preprint, "Determining the pathogenicity of variants of uncertain significance and identification of a founder variant in the epilepsy-associated gene SZT2"). - Modifier/susceptibility factors: None specifically established; phenotypic variability is attributed largely to residual SZT2 protein function (null/null genotypes → most severe DEE phenotype; genotypes retaining partial function → milder, later-onset partial epilepsy or isolated ID without seizures).

Environmental risk factors: Not established as primary causal factors; this is a genetically determined disorder, though consanguinity increases the probability of biallelic inheritance in homozygous cases.

Protective factors: No specific genetic or environmental protective factors are documented in the literature. Population databases (gnomAD) show SZT2 loss-of-function variants are rare/constrained (e.g., one reported allele frequency of 0.006%, 18/282,850 alleles, absent in homozygous state), consistent with negative selection against biallelic loss.

Gene-environment interactions: Not specifically studied for SZT2; general epilepsy-precipitant exposures (fever, sleep deprivation) may exacerbate seizures symptomatically but do not alter underlying genetic risk.

Sources: - SZT2 variants and genotype-phenotype correlation (PMC10198435, PMID:37213690) - Determining pathogenicity of VUS and founder variant in SZT2 (bioRxiv) - Clinical phenotype and genetic characteristics of SZT2-related diseases (ScienceDirect, 2023)

3. Phenotypes

Core phenotype triad (present in the large majority of reported cases):

Phenotype	HPO term (suggested)	Notes
Epilepsy / seizures	HP:0001250 (Seizure)	Onset typically within the first year(s) of life; median onset ~5 months in null/null genotypes vs. ~36 months in non-null genotypes
Global developmental delay	HP:0001263	Most common presenting feature across cohorts
Intellectual disability	HP:0001249	Severity ranges mild–severe, correlating with genotype
Macrocephaly	HP:0000256	A near-defining feature, often postnatal-onset
Dysmorphic/thick-short corpus callosum	HP:0007370 / HP:0002079 (Abnormal corpus callosum morphology)	"Thick and short" corpus callosum with persistent cavum septum pellucidum described as relatively specific MRI signature
Cortical malformation (cortical dysplasia, periventricular nodular heterotopia)	HP:0002539 (Focal cortical dysplasia), HP:0002185 (Periventricular nodular heterotopia)	More frequent in the severe null/null subgroup
Hypotonia	HP:0001252	Reported in a substantial minority (e.g., 15/58 in one pooled cohort)
Progressive leukoencephalopathy / delayed or lost central myelination	HP:0002352 or custom (white matter abnormality)	Described by Pizzino et al. 2018 as a novel, serially-documented finding (PMID:29696782)
Dysmorphic facial features	HP:0001999	Variably reported
Autism spectrum features	HP:0000717	Reported in some individuals, including a boy with ID, seizures, and autistic features
Status epilepticus susceptibility	HP:0032667	High susceptibility to status epilepticus repeatedly noted as a relatively distinctive feature

Seizure semiology. Reported seizure types span infantile spasms/tonic seizures, focal (partial) seizures — including migrating focal seizures of infancy in one familial report — and generalized seizure types; many patients progress to drug-resistant epilepsy with frequent status epilepticus.

Genotype-phenotype correlation (Wang et al. 2023, PMC10198435, PMID:37213690; n=50 pooled cases): - Biallelic null (LoF/LoF), n=9: median seizure onset 5 months; DEE phenotype; 8/9 (89%) refractory seizures; frequent infantile spasms/tonic seizures and diffuse cortical dysplasia/periventricular nodular heterotopia. - Biallelic with one null variant, n=7: median onset 12 months; DEE; 2/7 (29%) refractory. - Biallelic non-null (missense/missense), n=20: median onset 36 months; more often a milder partial-epilepsy phenotype with better developmental outcome; 7/17 (41%) refractory; 3/20 had no seizures at all; normal neurodevelopment more common. - Statistically, null genotypes showed significantly higher seizure refractoriness than non-null (p=0.049) and than mixed genotypes (p=0.035).

Phenotypic spectrum breadth. The disorder spans from severe early-infantile DEE with profound ID to milder intellectual disability without epilepsy at all, a range attributed to residual SZT2 protein function (Insight into Genetic Mutations of SZT2: Is It a Syndrome?, PMC10525120).

Frequency data from pooled cohorts: In one literature-review cohort, global developmental delay was reported in 27 patients and hypotonia in 15, with seizures noted as the predominant hallmark in 26 patients (of the reviewed set).

Quality of life impact. No disease-specific QOL instrument data were identified; qualitatively, the severe end of the spectrum (refractory DEE with severe ID, motor impairment, and recurrent status epilepticus) carries substantial burden on daily functioning, feeding, mobility, and caregiver burden, typical of severe pediatric DEEs generally.

Sources: - SZT2 variants genotype-phenotype correlation (PMID:37213690) - Pizzino et al. 2018, leukoencephalopathy (PMID:29696782) - Novel SZT2 mutations, three DEE patients (PMC6732301) - A novel possible familial cause of epilepsy of infancy with migrating focal seizures related to SZT2 (PubMed PMID:33681650) - Clinical phenotype and genetic characteristics of SZT2 related diseases (ScienceDirect 2023) - Insight into Genetic Mutations of SZT2: Is It a Syndrome? (PMC10525120)

4. Genetic/Molecular Information

Causal gene: SZT2 (HGNC:29175), chromosome 1p34.2, OMIM gene 615463.

Protein: SZT2 encodes a large (~378 kDa) scaffold protein with no significant sequence homology to other known proteins; it functions as the core/largest subunit of the KICSTOR complex (KPTN, ITFG2, C12orf66, SZT2-containing regulator of mTORC1).

Variant classification: - Type/class: Predominantly truncating (nonsense, frameshift, canonical splice-site) loss-of-function variants; missense variants also reported, generally associated with milder phenotypes (partial/residual function). - Pathogenicity assessment: ACMG/AMP framework applied in case reports; a dedicated study specifically addressed classification of SZT2 variants of uncertain significance (VUS) and identified a founder allele. - Population frequency: SZT2 loss-of-function variants are rare and constrained in gnomAD (example variant heterozygous frequency 0.006%, 18/282,850 alleles; absent in homozygous state), consistent with a rare autosomal recessive disease allele architecture. - Origin: Germline (biallelic inherited or, less commonly, de novo on one allele with an inherited second variant); no somatic SZT2-driven disease has been reported. - Functional consequence: Predominantly loss of function, producing a hypomorphic-to-null KICSTOR complex and consequent failure of amino-acid-sensing-dependent mTORC1 inhibition — i.e., constitutive/pathological mTORC1 gain-of-function at the pathway level, despite the causal SZT2 variant itself being LoF.

Molecular mechanism (KICSTOR/mTORC1): SZT2 is required, together with KPTN, ITFG2, and C12orf66, to recruit GATOR1 to the lysosomal surface, which under amino-acid-replete/-deplete conditions regulates mTORC1 localization and activity (Wolfson et al., Nature 2017, PMID:28199306). Loss of any KICSTOR component — including SZT2 — causes mislocalization of GATOR1 and renders mTORC1 constitutively lysosome-bound and active regardless of nutrient status, i.e., loss of the normal negative-feedback brake on mTORC1 (Frankel et al./PLOS ONE, PMC6701784; "The SZT2 Interactome Unravels New Functions of the KICSTOR Complex," PMC8534408).

Modifier genes: None specifically validated; phenotypic severity correlates instead with the degree of residual SZT2/KICSTOR function conferred by the specific variant combination (null/null vs. null/hypomorph vs. hypomorph/hypomorph).

Epigenetic information: No SZT2-specific DNA methylation or chromatin studies were identified in the current literature.

Chromosomal abnormalities: SZT2-related disease is caused by point mutations/small indels rather than large chromosomal rearrangements in the majority of reports; large deletions encompassing SZT2 have not been prominently described as a distinct mechanism in the reviewed literature.

Suggested ontology terms: - Gene: HGNC:29175 (SZT2) - GO Biological Process: GO:0034198 (cellular response to amino acid starvation), GO:1904262 (negative regulation of TORC1 signaling) - GO Molecular Function: scaffold/protein-binding function (no enzymatic activity) - GO Cellular Component: GO:0005765 (lysosomal membrane) — KICSTOR/GATOR1 localize to the lysosomal surface

Sources: - KICSTOR recruits GATOR1 to the lysosome (Nature 2017, PMID:28199306) - Constitutive activation of mTORC1 signaling induced by biallelic LoF SZT2 mutations (PLOS ONE, PMC6701784) - The SZT2 Interactome Unravels New Functions of the KICSTOR Complex (PMC8534408) - Determining pathogenicity of VUS / founder variant in SZT2 (bioRxiv)

5. Environmental Information

No specific environmental toxin, infectious agent, or occupational/lifestyle exposure has been implicated as a cause or trigger of SZT2-related DEE18 — it is a fully genetically determined disorder. As with most genetic epilepsies, generic seizure-precipitating factors (febrile illness, sleep deprivation, intercurrent infection) may exacerbate seizure frequency/severity in affected individuals but are not disease-causal. No infectious agents are implicated in pathogenesis.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Molecular trigger: Biallelic loss-of-function SZT2 variants → loss/reduction of functional SZT2 protein.
Complex disruption: Loss of SZT2 destabilizes/disrupts the KICSTOR complex (SZT2–KPTN–ITFG2–C12orf66), which normally scaffolds GATOR1 to the lysosomal membrane in an amino-acid-sensitive manner.
Pathway dysregulation: Without functional KICSTOR, GATOR1 fails to localize to the lysosome and cannot restrain Rag GTPase-dependent mTORC1 recruitment; mTORC1 becomes constitutively lysosome-bound and active regardless of nutrient/amino-acid status ("Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2," PLOS ONE, PMC6701784).
Cellular consequences: Persistent mTORC1 hyperactivation drives abnormal neural progenitor proliferation and cell growth. A 2026 brain-organoid study found SZT2-mutant organoids show overproduction of outer radial glial cells (oRGCs) in the subventricular-zone-like layer via mTORC1 activation, offering a cellular explanation for the megalencephaly/macrocephaly and cortical malformation (cortical dysplasia, periventricular nodular heterotopia) phenotypes ("Brain organoid models of SZT2-related disease reveal an overproduction of outer radial glial cells through mTORC1 activation," PMID:41535455).
Network-level consequences: Aberrant progenitor expansion and disrupted neuronal migration are hypothesized to contribute to the cortical dysplasia/heterotopia and dysmorphic (thick/short) corpus callosum seen on neuroimaging.
Circuit-level consequence — hyperexcitability: Independent of the developmental malformation, the original mouse-genetics discovery of Szt2 found that loss-of-function confers a lowered seizure threshold and enhanced kindling/epileptogenesis, indicating a direct role for SZT2/mTORC1 dysregulation in neuronal excitability, not solely secondary to structural brain malformation.
Clinical manifestation: The combination of macrocephaly, structural brain malformation, and intrinsic hyperexcitability manifests as early-onset, often drug-resistant epilepsy plus global developmental delay/intellectual disability. In a subset, ongoing white-matter pathology contributes a progressive leukoencephalopathy component (Pizzino et al. 2018, PMID:29696782).

Cell types/biological processes involved: - Outer radial glial cells (oRGCs) — CL:0002605-type outer/basal radial glia analog; overproduced under mTORC1 hyperactivation, implicated in cortical expansion/malformation. - Cortical neurons — abnormal migration underlying heterotopia/dysplasia. - Oligodendrocytes/myelinating cells — implicated in the progressive leukoencephalopathy phenotype.

Suggested GO terms: GO:1904262 (negative regulation of TORC1 signaling — disrupted), GO:0031929 (TOR signaling), GO:0021987 (cerebral cortex development), GO:0021795 (cerebral cortex cell migration). Suggested CL terms: CL:0000030 (glioblast)/outer radial glia analog, CL:0000540 (neuron), CL:0002453 (oligodendrocyte precursor cell).

Molecular profiling / advanced technologies: - iPSC models: iPSC lines have been generated from a family with resistant epileptic encephalopathy caused by compound heterozygous SZT2 mutations, providing a patient-derived cellular resource for functional studies (PMC9654488). - Brain organoid models: 2026 Scientific Reports study using cerebral organoids derived from SZT2-mutant lines demonstrated the oRGC overproduction/mTORC1 mechanism described above (PMID:41535455). - Interactome/proteomics: "The SZT2 Interactome Unravels New Functions of the KICSTOR Complex" (PMC8534408) mapped SZT2 protein-protein interactions beyond the core KICSTOR members, suggesting additional non-canonical roles.

Sources: - KICSTOR/GATOR1/mTORC1 mechanism (Nature, PMID:28199306) - Constitutive mTORC1 activation from biallelic SZT2 LoF (PLOS ONE, PMC6701784) - Brain organoid oRGC overproduction via mTORC1 (PMID:41535455) - The SZT2 Interactome Unravels New Functions of the KICSTOR Complex (PMC8534408) - iPSC lines from SZT2 family (PMC9654488) - Pizzino et al. 2018, leukoencephalopathy (PMID:29696782)

7. Anatomical Structures Affected

Organ level: - Primary organ: Brain (central nervous system) — the sole primary site of pathology; this is a pure neurodevelopmental disorder without established involvement of other organ systems as a defining feature. - Body system: Nervous system (UBERON:0001016)

Tissue/cell level: - Cerebral cortex — cortical dysplasia, periventricular nodular heterotopia (UBERON:0000956 cerebral cortex) - Corpus callosum — dysmorphic, thick and short (UBERON:0002336) - Cerebral white matter — progressive demyelination/dysmyelination in a subset (leukoencephalopathy) - Septum pellucidum — persistent cavum septum pellucidum frequently noted on MRI (UBERON:0002619) - Cell populations: outer radial glial cells, cortical neurons, oligodendrocytes

Subcellular level: Lysosomal membrane (GO:0005765) — the site of KICSTOR/GATOR1/mTORC1 complex assembly and dysregulation.

Localization: Bilateral/diffuse cortical and white-matter involvement is typical (not unilateral/lateralized); macrocephaly is a whole-brain/whole-head finding.

Sources: - Pizzino et al. 2018 (PMID:29696782) - Basel-Vanagaite et al. 2013 (PMID:23932106) - Brain organoid oRGC study (PMID:41535455)

8. Temporal Development

Onset: - Congenital/perinatal macrocephaly may be noted at birth or emerge postnatally. - Seizure onset is typically within the first year(s) of life; genotype-stratified median onset ranged from ~5 months (null/null) to ~36 months (non-null/non-null) in the pooled genotype-phenotype study (PMID:37213690). - Onset pattern: generally subacute/insidious, with progressive developmental delay recognized alongside or shortly after seizure onset; some patients present with acute-onset status epilepticus.

Progression: - Disease course is typically chronic and, in the severe subgroup, progressive, with drug-resistant epilepsy, ongoing developmental impairment, and (in a subset) progressive loss of central myelination documented on serial MRI (Pizzino et al. 2018). - Milder (non-null genotype) cases can show a more stable course, sometimes without seizures at all or with better-controlled epilepsy and more typical developmental trajectories. - No formal staging system exists; severity is best captured by the genotype-correlated DEE-vs-partial-epilepsy dichotomy above.

Patterns: - Remission: Not typically described as spontaneous; seizure control, when achieved, is generally treatment-dependent (polytherapy, and in refractory cases dietary or device-based therapy). - Critical periods: Early infancy represents a critical window given the correlation between earlier onset and more severe, refractory disease; early diagnosis/genetic confirmation is emphasized in the literature to guide prognosis and family counseling.

Sources: - SZT2 genotype-phenotype correlation (PMID:37213690) - Pizzino et al. 2018 (PMID:29696782)

9. Inheritance and Population

Epidemiology: - Prevalence/incidence: No formal population-based prevalence or incidence estimate exists (not listed with a specific Orphanet numeric prevalence class in the sources reviewed); this is an ultra-rare disorder known almost exclusively through case reports/series. Cumulative literature reviews report on the order of 40–50 published patients worldwide as of the most recent systematic reviews (2023). - Because ascertainment is driven by clinical/research sequencing (epilepsy gene panels, exome/genome sequencing), true population prevalence is likely underestimated.

Inheritance pattern: Autosomal recessive. Both parents are typically unaffected heterozygous carriers; affected individuals carry biallelic (homozygous or compound heterozygous) pathogenic variants.

Penetrance/expressivity: - Penetrance for the general "SZT2-related neurodevelopmental disease" category with biallelic LoF appears high, but expressivity is highly variable, ranging from severe DEE to mild ID without seizures, correlating with variant type/residual function (genotype-phenotype data above).

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the reviewed SZT2 literature, though it remains a theoretical possibility relevant to recurrence-risk counseling for autosomal recessive disorders generally.

Founder effects: A founder SZT2 variant has been identified and characterized in a dedicated pathogenicity/VUS classification study, indicating population-specific enrichment of at least one recurrent allele.

Consanguinity: Homozygous genotypes (15 of 43 cumulative cases in one 2023 review) are enriched in the context of parental consanguinity, as expected for autosomal recessive disease; compound heterozygous genotypes (28/43) predominate in outbred populations.

Carrier frequency: Not precisely established population-wide; individual pathogenic alleles are rare in gnomAD (e.g., one variant at 0.006% allele frequency, 18/282,850 alleles, no homozygotes observed), consistent with an overall rare carrier frequency and strong purifying selection against biallelic loss-of-function.

Population demographics: - No specific ethnic or geographic enrichment beyond the founder-variant observation has been robustly established; reported cases span multiple ancestries including Chinese, Middle Eastern/Saudi, and other cohorts (e.g., "A novel homozygous mutation in SZT2 gene in Saudi family," Genes & Genomics 2018; "Genetic analysis of developmental and epileptic encephalopathy caused by novel biallelic SZT2 gene mutations in three Chinese Han infants," Neurological Sciences 2022). - Sex ratio: Approximately balanced in reported cohorts (e.g., one series: 16 female, 13 male patients plus 2 additional male cases), with no strong sex skew reported — consistent with autosomal (not X-linked) inheritance. - Age distribution: Predominantly pediatric ascertainment (infantile/early-childhood onset), reflecting the natural history of the disease.

Sources: - SZT2 variants genotype-phenotype correlation (PMID:37213690) - Clinical phenotype and genetic characteristics of SZT2 related diseases (ScienceDirect 2023) - Determining pathogenicity of VUS / founder variant in SZT2 (bioRxiv) - A novel homozygous mutation in SZT2 gene in Saudi family (Genes & Genomics) - Genetic analysis of DEE caused by novel biallelic SZT2 mutations in three Chinese Han infants (Neurological Sciences)

10. Diagnostics

Clinical tests: - MRI (brain imaging) is central to diagnosis: characteristic findings include macrocephaly, a thick and short corpus callosum, persistent cavum septum pellucidum, cortical dysplasia, periventricular nodular heterotopia, and, on serial imaging in some patients, progressive loss of central myelination (leukoencephalopathy) — described as a relatively specific/distinctive MRI signature for SZT2-related disease. - EEG: Used to characterize seizure semiology (focal, spasms/tonic, migrating focal seizures) and monitor for (sub)clinical status epilepticus, to which patients show high susceptibility. - No disease-specific biochemical biomarker or laboratory test exists; diagnosis is clinical (phenotype-driven) plus molecular confirmation.

Genetic testing: - Recommended approach: Given genetic heterogeneity of DEEs, epilepsy gene panels or exome/genome sequencing (WES/WGS) are the standard diagnostic route; SZT2 is included on comprehensive epilepsy panels (e.g., ARUP Comprehensive Epilepsy Panel). - WES/WGS utility: Most reported cases (including the founding Basel-Vanagaite et al. 2013 report) were identified via whole-exome sequencing, reflecting the practical necessity of unbiased sequencing for this genetically heterogeneous, phenotypically overlapping disease group. - Single-gene testing: Reasonable when phenotype (macrocephaly + thick/short corpus callosum + early DEE) is highly suggestive, but panel/exome approaches are more commonly used in practice due to phenotypic overlap with other DEEs. - Chromosomal microarray/karyotype/FISH: Not primary diagnostic tools for this single-gene disorder (used mainly to exclude alternative chromosomal etiologies). - Variant interpretation caveat: A significant proportion of reported SZT2 alleles required dedicated VUS-reclassification work (bioRxiv study), underscoring that variant curation (including checking against the identified founder allele) is an important part of diagnostic workup.

Omics-based diagnostics: Not yet part of routine clinical diagnosis; research use of iPSC/organoid models and interactome/proteomic studies has been used to functionally validate variant pathogenicity and elucidate mechanism (see Section 6), but these are research, not clinical, tools at present.

Clinical criteria/differential diagnosis: No formal consensus diagnostic criteria (DSM/ICD-specific) exist for SZT2-DEE; it is diagnosed as one of many genetic DEEs, differentiated from other macrocephaly-associated DEEs and other mTORopathies (e.g., PTEN hamartoma syndrome, tuberous sclerosis complex, DEPDC5/NPRL2/NPRL3-related focal epilepsies — the latter also acting through the GATOR1 pathway) by the combination of clinical phenotype, characteristic corpus callosum/MRI findings, and molecular confirmation.

Screening: No population-level newborn or carrier screening program specifically targets SZT2; carrier/prenatal testing would follow standard autosomal recessive genetic counseling principles once a familial variant is known.

Sources: - Basel-Vanagaite et al. 2013 (PMID:23932106) - Pizzino et al. 2018 (PMID:29696782) - SZT2 genotype-phenotype correlation (PMID:37213690) - ARUP Comprehensive Epilepsy Panel - Determining pathogenicity of VUS/founder variant in SZT2 (bioRxiv)

11. Outcome/Prognosis

Survival/mortality: No formal survival statistics (5-/10-year survival) were identified in the literature reviewed; mortality data specific to SZT2-DEE are not well characterized in published case series, though severe DEEs generally carry increased mortality risk related to refractory status epilepticus and comorbidities.

Morbidity/function: - The severe (null/null genotype) subgroup experiences substantial neurodevelopmental morbidity: profound intellectual disability, drug-resistant epilepsy, and high rates of status epilepticus. - The milder (non-null genotype) subgroup can have near-normal neurodevelopment, with epilepsy that is more often well-controlled, and a minority (3/20 in the pooled cohort) have no seizures at all. - No disease-specific quality-of-life instrument data were identified.

Disease course/complications: - Refractory/status epilepticus: A repeatedly noted, clinically important complication, with genotype-dependent frequency (89% refractory in null/null vs. 29–41% in other genotype groups). - Progressive leukoencephalopathy in a subset of patients adds an additional axis of neurological decline beyond the static structural malformation. - Recovery potential: Limited in the severe subgroup; developmental trajectory is more favorable in patients with at least one non-null (partially functional) allele.

Prognostic factors: - Genotype is the single strongest identified prognostic factor: presence and number of null (complete loss-of-function) alleles predicts earlier seizure onset, higher seizure refractoriness, and worse developmental outcome (PMID:37213690). - Presence of cortical dysplasia/periventricular nodular heterotopia on MRI correlates with the more severe null/null subgroup.

Sources: - SZT2 variants genotype-phenotype correlation (PMID:37213690) - Pizzino et al. 2018 (PMID:29696782)

12. Treatment

Pharmacotherapy: - Management is currently symptomatic/supportive, centered on standard antiseizure medications (ASMs), chosen and combined per seizure semiology; polytherapy is common given the high rate of drug resistance. - No SZT2-specific FDA-approved pharmacotherapy exists. - Mechanistically-targeted rationale (not yet an established standard of care): Because the disease mechanism converges on constitutive mTORC1 hyperactivation, mTOR inhibitors (rapamycin/sirolimus and analogs such as everolimus) — already used clinically for other mTORopathies such as tuberous sclerosis complex — represent a biologically plausible targeted therapy and are the subject of active preclinical investigation (e.g., in the SZT2 brain-organoid model), though a specific published clinical trial or case report of mTOR-inhibitor treatment in SZT2-DEE patients was not identified in this search; this should be treated as a mechanistic hypothesis for future/experimental use rather than an established treatment (NCIT:C1201, mTOR inhibitor drug class; NCIT:C825, Sirolimus).

Surgical/interventional: Not a primary treatment modality; epilepsy surgery is not typically applicable given diffuse/multifocal structural and mechanistic pathology, though it could be considered case-by-case if a discrete resectable focus is identified.

Supportive/rehabilitative care: - Multidisciplinary supportive care is central: physical therapy, occupational therapy, and speech/language therapy (NCIT:C15302 Physical Therapy; NCIT:C15315 Rehabilitation) address developmental delay and motor impairment. - Nutritional/feeding support as needed for children with severe DEE and hypotonia.

Non-pharmacological antiseizure approaches: - Ketogenic diet is a well-established option for drug-resistant pediatric epilepsies broadly (NCIT:C15447 Dietary Intervention) and would be a reasonable consideration in refractory SZT2-DEE, though disease-specific outcome data for SZT2 patients specifically were not identified in this search. - Vagus nerve stimulation (VNS) and other device-based approaches are standard considerations for refractory pediatric DEE generally (NCIT device-category term), again without SZT2-specific published outcome data identified here.

Experimental treatments: No SZT2-specific registered clinical trials were identified in this search. Given the mechanistic mTORC1 link, future translational work (building on the 2026 organoid model demonstrating mTORC1-driven oRGC overproduction) is a plausible direction for rapamycin/mTOR-inhibitor repurposing trials.

Treatment outcomes: Not systematically reported; response is presumed heterogeneous and largely reflects the genotype-correlated severity spectrum (refractory in the majority of null/null patients vs. more treatment-responsive in non-null genotypes).

Genetic counseling: An essential component of management for families, given autosomal recessive inheritance and defined recurrence risk (25% per pregnancy for carrier parents) (NCIT:C15240 Genetic Counseling).

Sources: - Constitutive activation of mTORC1 in SZT2 disease (PLOS ONE, PMC6701784) - Brain organoid mTORC1/oRGC study (PMID:41535455) - SZT2 genotype-phenotype correlation and refractoriness data (PMID:37213690)

13. Prevention

Primary prevention: No means of primary prevention exists for the underlying genetic lesion; risk-reduction is limited to reproductive/genetic counseling in families with a known pathogenic SZT2 variant.

Secondary prevention (early detection): Early recognition of the macrocephaly + early-onset seizures + characteristic corpus callosum MRI findings triad can prompt earlier genetic diagnosis, enabling earlier initiation of supportive/antiseizure management and family counseling — though no formal population screening program exists.

Genetic screening: - Carrier screening and prenatal diagnosis are applicable once a familial pathogenic variant is identified, particularly relevant in consanguineous families or those from populations with the identified founder allele. - Preimplantation genetic diagnosis (PGD) is a theoretical option for known-carrier couples, following standard practice for autosomal recessive Mendelian disorders, though SZT2-specific PGD case reports were not identified in this search.

Behavioral/public health interventions: Not applicable — this is a non-preventable genetic disorder with no modifiable environmental risk factor identified.

Prophylaxis: No disease-modifying prophylactic therapy currently exists; management remains reactive (seizure control, supportive care) rather than preventive.

14. Other Species / Natural Disease

Taxonomy: Mus musculus (NCBITaxon:10090) is the principal non-human species in which Szt2 has been studied.

Gene ortholog: Mouse Szt2 (MGI:3033336, "SZT2 subunit of KICSTOR complex") is the direct ortholog of human SZT2.

Natural/induced disease in other species: Szt2 was originally identified in mice via a chemical (ENU) mutagenesis screen as a gene conferring low seizure threshold; the semidominant phenotype was mapped to mouse Chromosome 4 and narrowed to a ~650 kb critical interval, identifying the 72-exon gene encoding a ~378 kDa protein. This is not a "naturally occurring" veterinary disease (unlike, e.g., breed-specific inherited disorders in dogs) but rather an induced/engineered mouse model used to establish SZT2's role in epileptogenesis before the human disease was characterized.

Comparative biology/pathology: - Szt2 mutant/knockout mice display: increased susceptibility to induced seizures, lower acute seizure threshold, enhanced kindling (more rapid epileptogenesis upon repeated subthreshold stimulation) compared to wild-type controls, and partial penetrance of prenatal lethality in homozygous null mice — indicating an essential developmental role beyond seizure threshold alone. - These mouse findings directly parallel the human phenotype of drug-resistant epilepsy and support a causal, conserved role for SZT2 in seizure susceptibility across species, predating and reinforcing the human genetic discovery. - Evolutionary conservation: The KICSTOR–GATOR1–mTORC1 amino-acid-sensing axis is broadly conserved across mammals, consistent with the mouse model's translational relevance.

Transmission/zoonotic potential: Not applicable — this is a non-infectious, cell-autonomous genetic disorder.

Sources: - Szt2 MGI Mouse Gene Detail (MGI:3033336) - KICSTOR recruits GATOR1 to lysosome (Nature, PMID:28199306) - Cure SZT2 patient advocacy — published studies list

15. Model Organisms

Mouse models: - ENU-mutagenized Szt2 mouse (the original discovery model): identified through a low-seizure-threshold phenotypic screen; homozygous mutants show reduced seizure threshold, enhanced kindling, and partial-penetrance embryonic/perinatal lethality. This model established the gene's name ("seizure threshold 2") and its role in epileptogenesis, and remains the primary in vivo genetic model linking SZT2 loss to seizure susceptibility. - Applications: modeling seizure threshold and kindling/epileptogenesis; less well suited (on its own) to modeling the human developmental/structural brain phenotype (macrocephaly, corpus callosum dysplasia), which appears to require the human/organoid cellular context to fully recapitulate.

Cellular/iPSC-derived models: - Patient-derived iPSC lines generated from a family with compound heterozygous SZT2 mutations and treatment-resistant epileptic encephalopathy, providing isogenic-adjacent human cellular material for downstream differentiation and functional studies (PMC9654488). - Cerebral/brain organoid models derived from SZT2-mutant lines (2026, Scientific Reports) directly recapitulate a human-relevant cellular phenotype: overproduction of outer radial glial cells via mTORC1 hyperactivation, offering a plausible cellular mechanism for the macrocephaly/cortical malformation axis of the human disease and a platform for testing mTOR-pathway-targeted interventions (PMID:41535455).

Model characteristics — phenotype recapitulation and limitations: - The mouse model strongly recapitulates the seizure-susceptibility/epileptogenesis component of the human disease (RECAPITULATES-level fidelity for the electrophysiological/seizure-threshold phenotype) but does not on its own model the macrocephaly, cortical dysplasia, or corpus callosum dysmorphism seen in human patients. - Brain organoids better recapitulate the cellular/developmental (progenitor overproduction, cortical malformation) arm of the human phenotype but lack circuit-level features (they cannot model seizures directly) and carry the general translational caveats of organoid systems (incomplete maturation, absence of vasculature/immune components, batch variability) — a HUMAN_MODEL_MISMATCH-type caveat as neither single model alone captures the full human phenotype; the mouse and organoid models are complementary, covering the seizure-susceptibility and developmental-malformation arms of pathophysiology respectively.

Resources: MGI (Mouse Genome Informatics) for the Szt2 mouse allele record (MGI:3033336); no dedicated SZT2 entries were identified in ZFIN, FlyBase, or WormBase in this search, suggesting the mouse and human iPSC/organoid systems represent the current state of the art for SZT2 disease modeling.

Sources: - Szt2 MGI Mouse Gene Detail (MGI:3033336) - Constitutive activation of mTORC1 signaling / SZT2 mouse and cellular data (PLOS ONE, PMC6701784) - iPSC lines from SZT2 family (PMC9654488) - Brain organoid oRGC overproduction via mTORC1 (PMID:41535455)

Summary of Key Ontology Term Suggestions for KB Curation

Category	Suggested terms
Disease	MONDO term not definitively confirmed in this search — verify current MONDO ID directly via OAK/Monarch before curation (candidate: DEE18/EIEE18 concept); OMIM:615476
Gene	HGNC:29175 (SZT2)
Phenotypes (HP)	HP:0001250 Seizure; HP:0000256 Macrocephaly; HP:0001263 Global developmental delay; HP:0001249 Intellectual disability; HP:0002079 Abnormal corpus callosum morphology; HP:0002539 Focal cortical dysplasia; HP:0002185 Periventricular nodular heterotopia; HP:0001252 Hypotonia; HP:0002352 abnormal CNS myelination-related term; HP:0032667 Status epilepticus; HP:0000717 Autism
GO Biological Process	GO:1904262 negative regulation of TORC1 signaling; GO:0034198 cellular response to amino acid starvation; GO:0021987 cerebral cortex development
GO Cellular Component	GO:0005765 lysosomal membrane
Cell types (CL)	outer radial glial cell (basal radial glia), neuron (CL:0000540), oligodendrocyte-lineage cell
Anatomy (UBERON)	UBERON:0000956 cerebral cortex; UBERON:0002336 corpus callosum; UBERON:0001016 nervous system
Treatment (NCIT)	NCIT:C15986 Pharmacotherapy (antiseizure medications); NCIT:C15447 Dietary Intervention (ketogenic diet, symptomatic use); NCIT:C15302 Physical Therapy; NCIT:C15315 Rehabilitation; NCIT:C15240 Genetic Counseling; mTOR inhibitor class (mechanistic/investigational, not yet clinically established for this indication)

Important curation caveat: This report relies on web search and article summaries rather than direct verification of every PMID snippet against cached abstracts. Per dismech SOP, every PMID cited above (23932106, 28199306, 29696782, 32402703, 37213690, 41535455, and others named) must be independently fetched via just fetch-reference and snippet-verified via just count-verified-snippets before being committed to a KB entry — do not paste any quote from this report directly into an evidence: block without that verification step. The exact MONDO identifier for this disease was not conclusively confirmed in this search and should be resolved via OAK (sqlite:obo:mondo) before curation.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	16
Resolved	16
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	1
Quoted claims found in source	1
Quoted claims not found in source	0
References weighed for topical relevance	16
On topic	14
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Experimental Models

Source YAML

References & Deep Research

Deep Research

SZT2-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Ontology Term Suggestions for KB Curation

Reference Validation